var title_f9_6_9312="Achalasia Gross";
var content_f9_6_9312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Achalasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross specimen of the esophagus from a patient with achalasia shows marked luminal dilatation of the proximal esophagus due to functional distal obstruction at the distal esophagus at the gastroesophageal junction (left).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9312=[""].join("\n");
var outline_f9_6_9312=null;
var title_f9_6_9313="Ramosetron: International drug information";
var content_f9_6_9313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ramosetron: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nasea (JP, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2677714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Ramosetron Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2677715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       5-HT",
"       <sub>",
"        3",
"       </sub>",
"       Receptor Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2677716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiemetic for the management of nausea and vomiting due to cancer chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2677718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: 100 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: 300 mcg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2677719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Injection: 300 mcg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Tablet, orally disintegrating: 100 mcg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10501 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9313=[""].join("\n");
var outline_f9_6_9313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369783\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677714\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677715\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677716\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677718\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821070\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677719\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10501\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10501|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_6_9314="RA ulnar styloid erosion x-ray";
var content_f9_6_9314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of ulnar styloid erosion in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiograph of the right wrist in the AP projection reveals a deformed and eroded ulnar styloid process (white arrow) in this patient who has rheumatoid arthritis. No other remarkable changes are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9314=[""].join("\n");
var outline_f9_6_9314=null;
var title_f9_6_9315="Identification of the thoracodorsal bundle";
var content_f9_6_9315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Identification of the thoracodorsal bundle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 557px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axillary vein has been exposed on its anterior surface, and dissection is carried out approximately 5 mm below the vein to expose the thoracodorsal bundle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9315=[""].join("\n");
var outline_f9_6_9315=null;
var title_f9_6_9316="Nail fold biopsy Freer elevator";
var content_f9_6_9316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Nail fold biopsy using a Freer elevator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of Informa Healthcare, from An Atlas of Diseases of the Nail, Rich P, Scher RK, New York, 2003; permission conveyed through Copyright Clearance Center, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9316=[""].join("\n");
var outline_f9_6_9316=null;
var title_f9_6_9317="ECG tutorial: Myocardial infarction";
var content_f9_6_9317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ECG tutorial: Myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9317/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9317/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9317/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9317/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9317/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9317/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/6/9317/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) is a central tool used to establish the diagnosis of myocardial ischemia or infarction. New abnormalities in the ST segment and T waves represent myocardial ischemia and may be followed by the formation of Q waves. However, in some patients with ischemia or infarction, especially if the left circumflex coronary artery is involved, the standard 12 lead electrocardiogram may be normal or nonspecific.",
"   </p>",
"   <p>",
"    The 2012 Joint European Society of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/World",
"    </span>",
"    Heart Federation",
"    <span class=\"nowrap\">",
"     (ESC/ACCF/AHA/WHF)",
"    </span>",
"    Task Force defined acute and prior MI and proposed new criteria necessary to secure the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9317/abstract/1\">",
"     1",
"    </a>",
"    ]. These include the presence of ST-T wave changes or a pathologic Q wave. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The findings on the ECG depend upon several characteristics of the ischemia or infarction including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration &mdash;",
"      <span class=\"nowrap\">",
"       hyperacute/acute",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       evolving/chronic",
"      </span>",
"     </li>",
"     <li>",
"      Size &mdash; amount of myocardium affected",
"     </li>",
"     <li>",
"      Localization &mdash; anterior versus inferior-posterior",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE MYOCARDIAL ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute ST elevation myocardial infarction (MI) presents with a current of injury pattern characterized by elevation of the ST segment in different leads, depending upon the location of the MI. The earliest change, infrequently seen since it occurs very early in the course of an acute infarction, is hyperacute T waves, which are tall, peaked, and symmetric, in at least two contiguous leads. The hyperacute T wave reflects a localized increase in potassium concentration in the area of the acute infarction.",
"   </p>",
"   <p>",
"    Thereafter, the ST segment elevates with the following appearance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initially there is elevation of the J point and the ST segment retains its concave configuration.",
"     </li>",
"     <li>",
"      Over time the ST segment elevation becomes more pronounced and the ST segment changes its morphology, becoming more convex or rounded upward.",
"     </li>",
"     <li>",
"      The ST segment may eventually become indistinguishable from the T wave; the QRS-T complex can actually resemble a monophasic action potential. This is a &ldquo;current of injury.&rdquo;",
"     </li>",
"     <li>",
"      An initial Q wave develops and there is a loss of R wave amplitude.",
"     </li>",
"     <li>",
"      The T wave becomes inverted, the ST segment returns to baseline, and a Q wave is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over time, there is continued evolution of ECG changes: the R wave amplitude becomes markedly reduced; the Q wave deepens; and the T wave remains inverted or becomes positive. These changes generally occur within the first two weeks after the event; however, in some patients they occur within a few hours of presentation.",
"   </p>",
"   <p>",
"    To be considered pathologic, the ST elevation, measured at the J point, must be &ge;.1mV, except for leads V2-V3, where it needs to be &ge;0.2mV in men &ge;40 years, &ge;0.25mV in men &lt;40 years, and &ge;0.15mV in women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9317/abstract/1\">",
"     1",
"    </a>",
"    ]. ST elevation can be caused by states other than myocardial ischemia, however. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16198?source=see_link\">",
"     \"ECG tutorial: ST and T wave changes\"",
"    </a>",
"    ). Because the ECG can have a changing morphology and may be non-diagnostic at times, serial ECGs should be performed to evaluate for changes suggestive of ischemia.",
"   </p>",
"   <p>",
"    The leads affected by these changes depend upon the location of the infarction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acute anterior wall MI presents with the changes in some or all of the precordial chest leads V1-V6 (",
"      <a class=\"graphic graphic_waveform graphicRef78453 \" href=\"UTD.htm?39/54/40810\">",
"       waveform 1",
"      </a>",
"      ). Reciprocal ECG changes occasionally are observed during the initial period of the acute infarction, presenting most often as depressions of the ST segments in the inferior leads (II, III, and aVF). Reciprocal changes are actually the same ST segment shifts as seen from a different angle or direction.",
"     </li>",
"     <li>",
"      An acute anteroseptal transmural MI presents with the changes in leads V1-V2 (",
"      <a class=\"graphic graphic_waveform graphicRef75683 \" href=\"UTD.htm?39/58/40874\">",
"       waveform 2",
"      </a>",
"      ). Reciprocal ECG changes occasionally are observed during the initial period of the acute infarction, presenting as depressions of the ST segments in the inferior (II, II, aVF) or lateral leads (I, aVL, V5, and V6).",
"     </li>",
"     <li>",
"      An acute anteroapical transmural MI presents with the changes in leads V3 and V4 (",
"      <a class=\"graphic graphic_waveform graphicRef52433 \" href=\"UTD.htm?40/32/41482\">",
"       waveform 3",
"      </a>",
"      ). Reciprocal ECG changes occasionally are observed during the initial period of the acute infarction, presenting as depressions of the ST segment in the inferior leads (II, III, aVF).",
"     </li>",
"     <li>",
"      An acute anterolateral transmural MI presents with the changes in leads V5 and V6, often in association with changes in leads I and aVL (",
"      <a class=\"graphic graphic_waveform graphicRef64952 \" href=\"UTD.htm?41/52/42826\">",
"       waveform 4",
"      </a>",
"      ). Reciprocal ECG changes occasionally are observed during the initial period of the acute infarction, presenting as depressions of the ST segment in the inferior leads (II, III, aVF), and in some cases in leads V1 and V2.",
"     </li>",
"     <li>",
"      An acute lateral transmural myocardial infarction presents with the changes confined to leads I and aVL (",
"      <a class=\"graphic graphic_waveform graphicRef82413 \" href=\"UTD.htm?41/53/42842\">",
"       waveform 5",
"      </a>",
"      ). Reciprocal ECG changes occasionally are observed during the initial period of the acute infarction, presenting as ST segment depressions in the inferior leads (II, III and aVF) or leads V1 and V2.",
"     </li>",
"     <li>",
"      An acute inferior wall transmural myocardial infarction presents with the changes in leads II, III, and aVF (",
"      <a class=\"graphic graphic_figure graphicRef57189 \" href=\"UTD.htm?41/44/42698\">",
"       figure 1",
"      </a>",
"      ). Reciprocal ECG changes occasionally are observed during the initial period of the acute infarction, presenting with ST segment depressions in leads I and aVL. The ST segment depression in the precordial leads V1 to V2 may be reciprocal, but more likely represents true posterior wall involvement (which may be diagnosed by ST elevation in leads V7 to V9) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9317/abstract/2\">",
"       2",
"      </a>",
"      ]. In addition, there may be the presence of ST elevation in the precordial chest leads V1 to V2. Involvement of the right ventricle may occur with an inferior wall myocardial infarction, and is confirmed by the presence of ST segment elevation in V3R and V4R. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"       \"Right ventricular myocardial infarction\"",
"      </a>",
"      .) The duration of ST elevation in the right precordial leads may be shorter compared to the inferior leads, and, therefore, a right sided ECG should be obtained as soon as possible after inferior wall ST elevation is noted.",
"     </li>",
"     <li>",
"      An acute posterior wall transmural myocardial infarction reflecting left circumflex coronary artery involvement may be missed on a typical ECG. Posterior lead ECG (leads V7-V9) should be completed if there is a high degree of suspicion or if ST depression is present in V1-3. The criteria for ST elevation in leads V7-9 are &ge;0.05mV in men over 40 years and women and ST elevation of &ge;0.1mV for men &lt;40 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The electrocardiographic changes that occur in patients who sustain a non-ST elevation MI are different. T wave flattening or inversion typically precedes ST segment depression. Q waves are typically absent but can occur, and the duration of the ST and T wave changes are variable. The ST segment is horizontal or down-sloping, &ge;0.05mV in two contiguous leads, and frequently associated with T wave inversion &ge;0.1mV and prominent R waves or",
"    <span class=\"nowrap\">",
"     R/S",
"    </span>",
"    ratio &gt;1 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9317/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466159\">",
"    <span class=\"h2\">",
"     Post-ischemic T wave inversions",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an episode of clinical ischemia, some patients may develop T wave inversions &gt;0.5mV in leads V1-V4, and occasionally to V5. The T waves are frequently deep and symmetric, with QT prolongation. This ECG pattern is seen after the chest pain has subsided and there is a &ldquo;post-ischemic state&rdquo; with no features of ST elevation or depression. This is also known as Wellens&rsquo; sign. It is associated with proximal left anterior descending stenosis and impending acute anterior wall infarct, though it is also seen in those with intracranial hemorrhage and some cardiomyopathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466175\">",
"    <span class=\"h2\">",
"     ST changes in the setting of conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of left bundle branch block (LBBB) there are baseline ST-T abnormalities that can influence the ability to assess for ischemia. Three criteria have been developed to assess for infarct in the setting of LBBB. ST elevation &ge; 0.1mV in leads with a positive QRS complex, ST depression &ge;0.1mm in leads V1-V3, and ST elevation &ge;5mm with a negative QRS complex. In the setting of right bundle branch block or fascicular blocks, ST segment changes can still be interpreted normally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIOR MYOCARDIAL INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chronic MI is characterized by initial Q waves that are deep (&gt;1 mm) and broad (&gt;0.03 to 0.04 seconds). The Q waves are more likely to be diagnostic of a prior MI if there is also an inverted T wave in the same lead. The location of these changes is dependent upon the location of the MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36868?source=see_link\">",
"     \"Pathogenesis and diagnosis of Q waves on the electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An abnormal Q wave is defined by [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9317/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any Q wave in leads V2-V3 &ge;20 msec or QS complex in lead V2-V3",
"     </li>",
"     <li>",
"      In two contiguous leads, Q wave &ge;30 msec and &ge;0.1 mV deep, or QS complex in leads I, II, aVL, aVF, or V4 to V6",
"     </li>",
"     <li>",
"      R wave &ge;40 msec in V1-V2 and",
"      <span class=\"nowrap\">",
"       R/S&ge;1,",
"      </span>",
"      with a concordant positive T wave (in the absence of conduction abnormalities).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anterior wall MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chronic anterior wall infarction is diagnosed by the presence of initial deep and broad Q waves in any of the precordial leads (",
"    <a class=\"graphic graphic_waveform graphicRef66472 \" href=\"UTD.htm?40/36/41546\">",
"     waveform 6",
"    </a>",
"    ). In some cases there are no Q waves, but rather poor R wave progression across the precordium (the R wave amplitude does not increase progressively from leads V1-V3, to V4, V5 or V6). This situation must be distinguished from other causes of poor R wave progression, including late transition (clockwise rotation) or a normal variant (often seen in women). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link\">",
"     \"ECG tutorial: Miscellaneous diagnoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infrequently there may be reverse R wave progression where the R wave amplitude becomes progressively smaller from lead V2 or V3 to lead V6. Similar to the ECG of an acute infarction, the location of the Q waves establishes the area of infarcted myocardium; septum (V1-V2); apex (V3-V4); or anterolateral wall (V5-V6).",
"   </p>",
"   <p>",
"    The ST segment typically is isoelectric. However, an aneurysm is suspected if it remains elevated greater than three weeks after the acute event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anterolateral wall MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;An old anterolateral wall infarction typically is diagnosed by the presence of Q waves that are deep and broad in the anterolateral precordial leads V4-V6. However, the Q waves may extend across the entire precordium and are usually associated with inverted T waves. In addition, there may be Q waves and T wave inversions in leads I and aVL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lateral wall MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;An old lateral wall infarction is diagnosed by the presence of initial Q waves which are deep and broad in leads I and aVL (",
"    <a class=\"graphic graphic_waveform graphicRef55529 \" href=\"UTD.htm?40/61/41946\">",
"     waveform 7",
"    </a>",
"    ). If the Q waves are very deep (or complex), the axis appears to be rightward. This has been termed a periinfarction block. However, if the R wave in these leads is small (ie, an rS complex), the rightward axis (&gt;+90&ordm;) is by definition a left posterior fascicular block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37687?source=see_link&amp;anchor=H12#H12\">",
"     \"ECG tutorial: Basic principles of ECG analysis\", section on 'Axis'",
"    </a>",
"    .) There is also an inverted T wave in these leads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Inferior wall MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;An old inferior wall MI is diagnosed by the presence of initial Q waves which are deep and broad in the inferior leads II, III, and aVF (",
"    <a class=\"graphic graphic_waveform graphicRef81282 \" href=\"UTD.htm?39/35/40506\">",
"     waveform 8",
"    </a>",
"    ). There are usually inverted T wave associated with the Q waves. If the R wave amplitude is reduced, the QRS complex (Qr) may appear to have a leftward axis (&gt;-30&ordm; the left axis is actually the result of the infarction and not a conduction abnormality; it is known as a periinfarction block). If the axis is very leftward (&gt;-30 &ordm; as a result of a small r and deep S wave [rS complex] in leads II and aVF), then this is a conduction abnormality termed a left anterior fascicular block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37687?source=see_link&amp;anchor=H12#H12\">",
"     \"ECG tutorial: Basic principles of ECG analysis\", section on 'Axis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not uncommon to see a Q wave in lead III only in patients who have not had a MI. The depth of this Q wave usually varies with respiration (respiratory Q wave). It represents a nonspecific normal finding. A diagnosis of inferior MI can only be made if there are also Q waves in either of the other inferior leads.",
"   </p>",
"   <p>",
"    Q waves may resolve within one year after an inferior wall MI in up to 30 percent of cases. The only remaining abnormalities in these instances are flattened or inverted T waves and ST segment changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Posterior wall MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;An old posterior wall MI is diagnosed when there is a tall R wave in V1-V2",
"    <span class=\"nowrap\">",
"     (R/S",
"    </span>",
"    &gt;1.0) (",
"    <a class=\"graphic graphic_waveform graphicRef68277 \" href=\"UTD.htm?42/9/43162\">",
"     waveform 9",
"    </a>",
"    ). Frequently there is also evidence of an inferior wall infarction. Other causes for a tall R wave in these leads, including right ventricular hypertrophy, dextrocardia, Duchenne&rsquo;s muscular dystrophy, Wolff-Parkinson-White pattern, hypertrophic cardiomyopathy, lead misposition, or early transition (counterclockwise rotation), must be considered in these patients. (See ECG tutorial: Miscellaneous diagnoses\"). The finding of Q waves and ST segment changes in leads V7 to V9 is helpful in diagnosing a true posterior MI(",
"    <a class=\"graphic graphic_table graphicRef72039 \" href=\"UTD.htm?11/27/11707\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9317/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Septal Q waves",
"    </strong>",
"    &mdash; Septal Q waves are physiologic Q waves, &lt;30 msec and &lt;25 percent the height of the associated R wave amplitude, seen in leads I, aVL, aVF, and V4-V6. They demonstrate the normal pattern of initial depolarization of the ventricular myocardium from the left to the right of the septum and do not represent a prior myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9283?source=see_link&amp;anchor=H4#H4\">",
"     \"ECG tutorial: Physiology of the conduction system\", section on 'Ventricular activation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15624833\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute ST-elevation myocardial infarction is characterized by the following evolutionary changes (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute myocardial ischemia'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hyperacute T waves, which are tall, peaked, and symmetric.",
"     </li>",
"     <li>",
"      Elevation of the ST segment in contiguous leads, depending upon the location of the MI. The ST elevation is at first concave and then becomes convex, merging with the T wave (current of injury).",
"     </li>",
"     <li>",
"      Development of Q waves and T wave inversions as the ST segments return to baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The electrocardiographic changes that occur in patients who sustain a non-ST elevation MI are different. T wave flattening or inversion typically precedes ST segment depression. Q waves are typically absent but can occur, and the duration of the ST and T wave changes is variable.",
"     </li>",
"     <li>",
"      A chronic MI, or infarction of indeterminate age, is characterized by initial Q waves that are deep (&gt;1 mm) and broad (&gt;0.03 to 0.04 seconds). The Q waves may be associated with an inverted T wave. The location of these changes is dependent upon the location of the MI. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prior myocardial infarction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320650625\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Philip J. Podrid for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9317/abstract/1\">",
"      Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9317/abstract/2\">",
"      Casas RE, Marriott HJ, Glancy DL. Value of leads V7-V9 in diagnosing posterior wall acute myocardial infarction and other causes of tall R waves in V1-V2. Am J Cardiol 1997; 80:508.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2125 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9317=[""].join("\n");
var outline_f9_6_9317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15624833\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE MYOCARDIAL ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H466159\">",
"      Post-ischemic T wave inversions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H466175\">",
"      ST changes in the setting of conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIOR MYOCARDIAL INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anterior wall MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anterolateral wall MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lateral wall MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Inferior wall MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Posterior wall MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15624833\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H320650625\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2125\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2125|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/44/42698\" title=\"figure 1\">",
"      Acute inferior MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2125|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/27/11707\" title=\"table 1\">",
"      Causes and diagnosis of tall R waves in V1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2125|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/54/40810\" title=\"waveform 1\">",
"      Acute anterior MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/58/40874\" title=\"waveform 2\">",
"      Acute anteroseptal MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/32/41482\" title=\"waveform 3\">",
"      Acute anteroapical MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/52/42826\" title=\"waveform 4\">",
"      Acute anterolateral MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/53/42842\" title=\"waveform 5\">",
"      Acute lateral MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/36/41546\" title=\"waveform 6\">",
"      Old anterior MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/61/41946\" title=\"waveform 7\">",
"      Old lateral MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/35/40506\" title=\"waveform 8\">",
"      Old inferior MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/9/43162\" title=\"waveform 9\">",
"      Old posterior MI tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37687?source=related_link\">",
"      ECG tutorial: Basic principles of ECG analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9283?source=related_link\">",
"      ECG tutorial: Physiology of the conduction system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16198?source=related_link\">",
"      ECG tutorial: ST and T wave changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36868?source=related_link\">",
"      Pathogenesis and diagnosis of Q waves on the electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_6_9318="ECG RMVT from LVOT";
var content_f9_6_9318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) recorded in a patient with repetitive monomorphic ventricular tachycardia (RMVT) arising from the left ventricular outflow tract (LVOT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This electrocardiogram (ECG) illustrates repetitive monomorphic ventricular tachycardia (RMVT) with a right bundle, inferior axis morphology signifying its left ventricular site of origin. This VT was localized to the area of the aorto-mitral continuity in the left ventricular outflow tract (LVOT).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9318=[""].join("\n");
var outline_f9_6_9318=null;
var title_f9_6_9319="Severe acute rejection";
var content_f9_6_9319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ITx severe acute rejection (low power view)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loss of surface epithelium with denudation of the mucosa layer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Farrukh Khan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9319=[""].join("\n");
var outline_f9_6_9319=null;
var title_f9_6_9320="Prevalence and evaluation of ventricular premature beats";
var content_f9_6_9320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevalence and evaluation of ventricular premature beats",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9320/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9320/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9320/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9320/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/6/9320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs) are triggered from the ventricular myocardium in a variety of situations. Also called ventricular premature complexes, premature ventricular complexes (PVCs), ventricular premature depolarizations, or ventricular extrasystoles, VPBs are common and occur in a broad spectrum of the population. This includes patients without structural heart disease and those with any form of cardiac disease, independent of severity.",
"   </p>",
"   <p>",
"    The prevalence and mechanisms of VPBs, along with the evaluation of patients with VPBs, are presented here. The electrocardiographic features, clinical significance, and treatment of VPBs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=see_link&amp;anchor=H1#H1\">",
"     \"ECG tutorial: Ventricular arrhythmias\", section on 'Premature ventricular contractions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of VPBs is directly related to the study population, the detection method, and the duration of observation. The following findings were noted in a review of 15,792 middle-aged subjects (45 to 65 years of age) in the Atherosclerosis Risk in Communities (ARIC) study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall prevalence of any VPB on a two minute electrocardiogram (ECG) was approximately 6 percent; the prevalence of more frequent or complex VPBs (multiformed, couplets, or nonsustained ventricular tachycardia) was approximately 3 and 0.8 percent, respectively.",
"     </li>",
"     <li>",
"      VPBs were more frequent in men than women, in African-Americans compared with whites, and in those with organic heart disease.",
"     </li>",
"     <li>",
"      The prevalence of VPBs increased with age (34 percent increase for each five year increment in age) and in the presence of other factors, such as faster sinus rate, hypokalemia, hypomagnesemia, and hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, prevalence estimates in epidemiologic studies are of uncertain accuracy since the ability to detect VPBs is dependent upon the duration of observation. The longer an individual is monitored (eg, 24 hours of ambulatory monitoring), the more likely that VPBs will be detected.",
"   </p>",
"   <p>",
"    In epidemiologic studies, a two minute rhythm strip is often used to detect VPBs. The utility of this approach was assessed in a series of 242 patients referred for ambulatory ECG monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/2\">",
"     2",
"    </a>",
"    ]. The presence of VPBs on a two-minute rhythm strip is an insensitive predictor of VPBs on 24 hour monitoring. Thus, a two minute ECG rhythm strip is",
"    <strong>",
"     not",
"    </strong>",
"    a useful clinical screening tool to detect VPBs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;VPBs are infrequent in patients with no known heart disease, occurring in approximately 1 percent of persons on routine 12-lead ECG of 30 to 60 seconds duration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. By comparison, when 24-hour ambulatory monitoring is used, up to 80 percent of apparently healthy people have VPBs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. There is an age-related increase in the prevalence of VPBs in normal individuals and those with underlying heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/1,3,6,7\">",
"     1,3,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mitral valve prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;All forms of ventricular as well as supraventricular arrhythmia are common in patients with mitral valve prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/8\">",
"     8",
"    </a>",
"    ]. VPBs are seen in 58 to 89 percent of these patients, and complex ventricular arrhythmia (multiformed VPBs, couplets or nonsustained ventricular tachycardia) occurs in 30 to 56 percent. Although frequent VPBs have been reported in up to 89 percent of adults with mitral valve prolapse, it is unclear if any arrhythmia, including VPBs, is more common in patients with mitral valve prolapse than in normals. However, patients with mitral valve prolapse who have redundant mitral leaflets and mitral regurgitation may have an increased frequency and complexity of VPBs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/9\">",
"     9",
"    </a>",
"    ]. In this setting, the frequency of VPBs is related to the hemodynamic abnormality and not the prolapse itself. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypertension and LVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypertension have more frequent VPBs, with hypertensive patients in the ARIC study having a 23 percent increase in the prevalence of VPBs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the frequency and complexity of VPBs in hypertensive patients are likely related to the presence of left ventricular hypertrophy (LVH) rather than hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Up to 40 percent of patients with hypertension and normal left ventricular mass have frequent VPBs, but they are more often observed when there is LVH, particularly when associated with ECG abnormalities such as ST segment depression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with LVH also have a higher risk of sudden cardiac death; however, the impact of VPBs in this setting remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical significance and treatment of ventricular premature beats\", section on 'Left ventricular hypertrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;VPBs are common in patients after an acute myocardial infarction (MI) with a reported incidence as high as 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/12\">",
"     12",
"    </a>",
"    ]. The incidence of complex or repetitive VPBs, particularly nonsustained ventricular tachycardia (NSVT), is 1 to 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. VPBs commonly occur following reperfusion of an occluded artery and in this setting do not require antiarrhythmic treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with larger infarctions have a greater number of VPBs in the peri-infarct period [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/15\">",
"     15",
"    </a>",
"    ]. Following hospital discharge, there appears to be an increase in the frequency of ventricular ectopy during the recovery phase. Compared to a predischarge evaluation, for example, there was a greater incidence of VPBs and NSVT one to six months after the acute event [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to late onset VPBs in patients with a prior MI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4456148\">",
"    <span class=\"h2\">",
"     Chronic CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of VPBs in patients with coronary heart disease (CHD) varies considerably based upon the method of detection. They are infrequently seen on an ECG; by comparison, they can be detected in approximately 90 percent of such patients on a 24-hour ambulatory monitor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/17\">",
"     17",
"    </a>",
"    ]. This prevalence is similar to that seen in patients without know CHD. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Normal individuals'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    VPBs become more frequent during episodes of overt or silent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Acute MI'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dilated cardiomyopathy and HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of VPBs is increased in patients with a dilated cardiomyopathy and heart failure (HF), regardless of the etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. VPBs, which may be frequent and complex (including NSVT), occur in 70 to 95 percent of patients with advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link&amp;anchor=H3#H3\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\", section on 'Ventricular premature beats'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy results in various degrees of a thickened, hypertrophied myocardium and diastolic dysfunction. In contrast to the normal architecture and parallel muscle fibers found in the thickened myocardium resulting from physiologic hypertrophy, the architecture in a hypertrophic myocardium is grossly abnormal, and the muscle fibers are disarrayed. As a result, VPBs and other arrhythmias are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link&amp;anchor=H5#H5\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'Ventricular premature beats'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In congenital heart disease, VPBs can result from the primary defect or operative repair [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/26\">",
"     26",
"    </a>",
"    ]. The one congenital defect consistently associated with frequent VPBs is repaired tetralogy of Fallot, although VPBs have also been reported with congenital aortic stenosis, transposition of the great vessels, ventricular septal defect, and Eisenmenger's syndrome (regardless of the etiology). VPBs are uncommon in patients less than eight years of age, but those over the age of 30 have frequent VPBs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MECHANISMS FOR VPBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since invasive testing is rarely performed in patients with only simple VPBs, there is little information about the mechanisms of VPBs in humans. Information derived from experiments in animals suggests that the mechanisms by which VPBs are generated include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reentry",
"     </li>",
"     <li>",
"      Enhanced normal or abnormal automaticity",
"     </li>",
"     <li>",
"      Triggered activity resulting in afterdepolarizations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9829334\">",
"    <span class=\"h2\">",
"     Reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reentry is the most common mechanism for VPBs. Reentrant VPBs occur with conduction delay and unidirectional block, settings that are characteristically seen in patients with a healed myocardial infarction. A wave front may then perpetuate under the correct set of circumstances, such as the administration of a drug that prolongs conduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Enhanced automaticity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal automaticity is most probable with electrolyte abnormalities or acute ischemia and is enhanced by catecholamines. These conditions tend to lower the diastolic transmembrane voltage, resulting in premature depolarization. The principal site of VPB development due to abnormal automaticity is the Purkinje fiber layer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=see_link\">",
"     \"Enhanced cardiac automaticity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Triggered activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triggered activity is a more common mechanism for VPB development in humans than was previously appreciated. Early or late afterdepolarizations may occur in Purkinje cells or in the ventricular myocardium; such electrical activity may arise because of a number of conditions, including hypokalemia, ischemia, infarction, excess calcium, and drug toxicity (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or agents that prolong repolarization or the QT interval). If repetitive firing allows these afterdepolarizations to reach threshold potential, VPBs will be generated and may perpetuate if the proper conditions are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of VPBs is associated with several characteristic findings on history, physical examination, and electrocardiogram (ECG). Their occurrence may also facilitate the diagnosis of certain cardiac conditions, including hypertrophic cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;VPBs produce few or no symptoms in the vast majority of patients, although some individuals may be incapacitated by palpitations or dizziness. VPBs rarely cause true hemodynamic compromise, except when they occur frequently in a patient with severely depressed left ventricular function or when they are associated with an underlying bradycardia.",
"   </p>",
"   <p>",
"    The most common symptoms resulting from VPBs are palpitations secondary to the hypercontractility of a post-VPB beat or a feeling that the heart has stopped secondary to a post-VPB pause. Less often, frequent VPBs can result in a pounding sensation in the neck, lightheadedness, or near syncope. There is great variability as to when the symptoms are most prominent, although a quiet environment, such as at night while lying in bed, may make patients more aware of their ectopy. They are often more frequently appreciated when the subject is lying on their left side and the heart is closer to the chest wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of palpitations in adults\", section on 'Description'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Palpitations often provoke a great deal of anxiety that, in turn, may cause a vicious cycle of anxiety, catecholamine surges, and additional ectopy and palpitations. Patients may therefore report dizziness unrelated to any fall in cerebral perfusion pressure or blood flow. Gentle reassurance is of most benefit in these circumstances.",
"   </p>",
"   <p>",
"    Frequent VPBs have been associated with a reversible cardiomyopathy, even in the absence of sustained ventricular arrhythmias or symptoms. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link&amp;anchor=H14#H14\">",
"     \"Tachycardia-mediated cardiomyopathy\", section on 'Frequent ventricular ectopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular dissociation (if present) will result in variable intensity of the first heart sound (secondary to a changing PR interval) and in cannon \"A\" waves (due to almost simultaneous retrograde atrial and antegrade ventricular activation). The splitting of the second heart sound (S2) will also vary, depending upon whether the VPB has a right or left bundle branch morphology; a widely split S2 due to a delayed P2 may be appreciated if a right bundle branch block VPB occurs. An auscultated fully compensatory pause is present with most VPBs and is identified by the prolonged pause following the premature beat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3566020\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom VPBs are suspected should have an ECG performed, preferably while symptomatic if symptoms are present. Due to the brief nature of the test, VPBs may not be recorded during a standard ECG. In such cases, ambulatory monitoring for 24 or 48 hours will significantly increase the likelihood of detecting VPBs. Further testing is indicated only if underlying structural heart disease is suspected (eg, stress testing for suspected ischemic heart disease, echocardiography for suspected cardiomyopathy or congenital heart disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ECG should be part of the standard evaluation for any patient with suspected VPBs (",
"    <a class=\"graphic graphic_waveform graphicRef57511 \" href=\"UTD.htm?25/6/25704\">",
"     waveform 1",
"    </a>",
"    ). VPBs have the following ECG characteristics: (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=see_link\">",
"     \"ECG tutorial: Ventricular arrhythmias\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of more than 120 msec",
"     </li>",
"     <li>",
"      Bizarre morphology that does not resemble usual aberration (ie, a typical right or left bundle branch block)",
"     </li>",
"     <li>",
"      T wave in the opposite direction from the main QRS vector",
"     </li>",
"     <li>",
"      A fully compensatory pause (ie, the PP interval surrounding the VPB is twice the sinus PP interval); less frequently, the VPB is interpolated and does not alter the baseline sinus interval (ie, the PP interval surrounding the VPB is equal to the sinus PP interval)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pause results from an inability of the VPB to reset the sinus node, either from slow or absent retrograde conduction or the result of the VPB occurring late in the cardiac cycle. The sinus node fires on time, but the impulse it generates is unable to conduct to the ventricle since it has been rendered refractory by the VPB; hence a compensatory delay occurs (ie, the RR interval surrounding the VPB is twice the sinus RR interval).",
"   </p>",
"   <p>",
"    There are notable exceptions to these characteristic findings, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A less wide QRS complex that results from a VPB originating from the contralateral ventricle in a patient with a preexisting bundle branch block",
"     </li>",
"     <li>",
"      A pseudonormalized T wave in a patient with a prior MI",
"     </li>",
"     <li>",
"      A VPB that resets the sinus node and creates a noncompensatory pause",
"     </li>",
"     <li>",
"      An interpolated VPB that is unable to conduct retrogradely through the AV node and does not affect the underlying atrial or ventricular rate (",
"      <a class=\"graphic graphic_waveform graphicRef72768 \" href=\"UTD.htm?24/63/25592\">",
"       waveform 2",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=see_link&amp;anchor=H1#H1\">",
"       \"ECG tutorial: Ventricular arrhythmias\", section on 'Premature ventricular contractions'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Classically, unifocal VPBs have fixed coupling intervals with the preceding beat since the most frequent mechanism is localized reentry. By comparison, unifocal VPBs with variable coupling (resulting from variability in the timing of exit of the impulse into the ventricular myocardium) suggests a parasystolic focus due to ectopic tissue that exhibits autonomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     Parasystole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular parasystole represents an independent ectopic ventricular rhythm that competes with the sinus rhythm. It appears on the ECG as unifocal VPBs with a variable coupling cycle (the interval between the prior sinus beat and the premature beat varies) (",
"    <a class=\"graphic graphic_waveform graphicRef70928 \" href=\"UTD.htm?14/38/14953\">",
"     waveform 3",
"    </a>",
"    ). Parasystole may be caused by an automatic or triggered mechanism, may be modulated by other coincident cardiac rhythms, or may be irregularly manifest because of exit block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=see_link&amp;anchor=H7#H7\">",
"     \"ECG tutorial: Ventricular arrhythmias\", section on 'Ventricular parasystole'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Multifocal VPBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multifocal VPBs may originate from various sites, from one site with multiple exit points into the ventricular myocardium, or from changes in the pattern or direction of myocardial activation due to variables in ventricular electrophysiologic properties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     R on T phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;VPBs that begin at or near the apex of the T wave (termed the vulnerable period, which is a time when the energy threshold for ventricular fibrillation is reduced) are said to illustrate the \"R on T\" phenomenon. Although such VPBs were originally felt to carry a grave prognosis (being associated with ventricular fibrillation), much of this opinion was based upon experiments in which canine myocardium was rendered ischemic by coronary artery occlusion or the coronary care unit experience in patients with an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/27\">",
"     27",
"    </a>",
"    ]. Subsequent studies found that late coupled VPBs were equally as likely as R on T VPBs to initiate repetitive ventricular arrhythmia (particularly ventricular tachycardia (VT)) in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, these studies did not enroll patients with acute ischemia, and the association between early or late VPBs and VT was evaluated, but ventricular fibrillation was not.",
"   </p>",
"   <p>",
"    The R on T VPB is of importance in a patient with an acute myocardial ischemic event since it may be associated with a risk of polymorphic ventricular tachycardia or ventricular fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h4\">",
"     Bigeminy, trigeminy, and quadrigeminy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several specific VPB patterns have been described. One pattern, ventricular bigeminy, refers to a persistent alternation of normal and premature beats (ie, every other QRS complex is a VPB) (",
"    <a class=\"graphic graphic_waveform graphicRef51529 \" href=\"UTD.htm?12/44/13002\">",
"     waveform 4",
"    </a>",
"    ). The mechanism of this arrhythmia is assumed to be reentry since the coupling intervals between normal and ectopic beats are constant. When bigeminy occurs in patients with compromised ventricular function (especially in those with an intrinsically slow sinus rate), the alternating loss of an effective contraction can cause hemodynamic impairment. This is one of the few settings in which VPBs can provoke hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=see_link&amp;anchor=H2#H2\">",
"     \"ECG tutorial: Ventricular arrhythmias\", section on 'Ventricular bigeminy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ventricular trigeminy (two normal beats followed by a VPB) and quadrigeminy (three normal beats followed by a VPB) have also been described (",
"    <a class=\"graphic graphic_waveform graphicRef64181 \" href=\"UTD.htm?42/34/43559\">",
"     waveform 5",
"    </a>",
"    ). They rarely cause severe symptoms and have",
"    <strong>",
"     no known",
"    </strong>",
"    independent prognostic importance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3566083\">",
"    <span class=\"h3\">",
"     Ambulatory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In evaluating patients with suspected VPBs, 24 to 48 hours of ambulatory ECG monitoring significantly increases the likelihood of making the diagnosis, given the sporadic nature of VPBs in most patients. In addition, diurnal variability commonly results in an increased morning frequency of VPBs, and the number of VPBs on an ambulatory ECG recording may reveal great hourly and daily fluctuations on serial studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several factors may underlie the variability of VPB frequency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duration of monitoring &ndash; Variability in VPB frequency diminishes with increased duration of monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frequency of baseline VPBs &ndash; Random variability is related to the hourly frequency of VPBs at baseline; low and high frequencies of VPBs are poorly and highly reproducible, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/30,32\">",
"       30,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Duration of time between observations &ndash; Another factor influencing random variability is the duration of time between monitoring. Greater variability is associated with a longer time period between monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/33-35\">",
"       33-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changing substrate &ndash; Post myocardial infarction patients exhibit VPB variability due in part to a changing and evolving myocardial substrate. As an example, data from the Beta Blocker Heart Attack Trial (BHAT) found an increase in ectopy during the period of recovery from the acute infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9320/abstract/16,36\">",
"       16,36",
"      </a>",
"      ]. In addition to infarct healing and systemic metabolic fluctuations, further explanations for VPB variability include regression to the mean and a placebo effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     EP testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although electrophysiologic (EP) testing is rarely indicated for patients with VPBs, this arrhythmia does occur during studies being performed for other reasons. At EP study, the evaluation of a wide complex beat is based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An aberrantly conducted supraventricular beat is excluded if a short or negative HV interval is present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=see_link\">",
"       \"Overview of invasive cardiac electrophysiology studies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attention is then directed toward the AV relationship. If the atrium and ventricle are dissociated or if atrial activation follows ventricular activation, then ventricular preexcitation is excluded, and the beat is ventricular in origin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/23/39281?source=see_link\">",
"       \"Patient information: Ventricular premature beats (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3565692\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular premature beats (VPBs), also called ventricular premature complexes, premature ventricular complexes, ventricular premature depolarizations, or ventricular extrasystoles, are common and occur in a broad spectrum of the population, including patients without structural heart disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of VPBs is directly related to the study population, the detection method, and the duration of observation. When 24-hour ambulatory monitoring is used, up to 80 percent of apparently healthy people have VPBs, with an age-related increase in the prevalence. VPBs have also been frequently reported in association with numerous underlying cardiac pathologies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence and disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms by which VPBs are generated include reentry, enhanced or abnormal automaticity, and triggered activity resulting in afterdepolarizations. Reentry is the most common mechanism for VPBs. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mechanisms for VPBs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VPBs produce few or no symptoms in the vast majority of patients. When present, the most common symptoms resulting from VPBs are palpitations secondary to the hypercontractility of a post-VPB beat or a feeling that the heart has stopped secondary to a post-VPB pause. Less often, frequent VPBs can result in a pounding sensation in the neck, lightheadedness, or near syncope. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients in whom VPBs are suspected should have an ECG performed, preferably while symptomatic if symptoms are present. Due to the brief nature of the test, VPBs may not be recorded during a standard ECG. In such cases, ambulatory monitoring for 24 or 48 hours (or an event monitor for a longer duration) will significantly increase the likelihood of detecting VPBs. Further testing is indicated only if underlying structural heart disease is suspected (eg, stress testing for suspected ischemic heart disease, echocardiography for suspected cardiomyopathy or congenital heart disease). (See",
"      <a class=\"local\" href=\"#H3566020\">",
"       'Testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/1\">",
"      Simpson RJ Jr, Cascio WE, Schreiner PJ, et al. Prevalence of premature ventricular contractions in a population of African American and white men and women: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2002; 143:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/2\">",
"      Evenson KR, Welch VL, Cascio WE, Simpson RJ Jr. Validation of a short rhythm strip compared to ambulatory ECG monitoring for ventricular ectopy. J Clin Epidemiol 2000; 53:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/3\">",
"      HISS RG, LAMB LE. Electrocardiographic findings in 122,043 individuals. Circulation 1962; 25:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/4\">",
"      Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. N Engl J Med 2000; 343:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/5\">",
"      Sobotka PA, Mayer JH, Bauernfeind RA, et al. Arrhythmias documented by 24-hour continuous ambulatory electrocardiographic monitoring in young women without apparent heart disease. Am Heart J 1981; 101:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/6\">",
"      Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977; 39:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/7\">",
"      Glasser SP, Clark PI, Applebaum HJ. Occurrence of frequent complex arrhythmias detected by ambulatory monitoring: findings in an apparently healthy asymptomatic elderly population. Chest 1979; 75:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/8\">",
"      Schaal SF. Ventricular arrhythmias in patients with mitral valve prolapse. Cardiovasc Clin 1992; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/9\">",
"      Kligfield P, Hochreiter C, Kramer H, et al. Complex arrhythmias in mitral regurgitation with and without mitral valve prolapse: contrast to arrhythmias in mitral valve prolapse without mitral regurgitation. Am J Cardiol 1985; 55:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/10\">",
"      Messerli FH, Ventura HO, Elizardi DJ, et al. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/11\">",
"      McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/12\">",
"      Bigger JT Jr, Dresdale FJ, Heissenbuttel RH, et al. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis 1977; 19:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/13\">",
"      Eldar M, Sievner Z, Goldbourt U, et al. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. The SPRINT Study Group. Ann Intern Med 1992; 117:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/14\">",
"      Heidb&uuml;chel H, Tack J, Vanneste L, et al. Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence. Circulation 1994; 89:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/15\">",
"      Minisi AJ, Mukharji J, Rehr RB, et al. Association between extent of coronary artery disease and ventricular premature beat frequency after myocardial infarction. Am Heart J 1988; 115:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/16\">",
"      DeBusk RF, Davidson DM, Houston N, Fitzgerald J. Serial ambulatory electrocardiography and treadmill exercise testing after uncomplicated myocardial infarction. Am J Cardiol 1980; 45:547.",
"     </a>",
"    </li>",
"    <li>",
"     Marinchak RA, Rials SJ, Kowey PR. Asymptomatic ventricular ectopic activity and chronic ischemic heart disease. In: Management of Ventricular Arrhythmia, Brest A (Ed), FA Davis, Philadelphia 1992. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/18\">",
"      Stern S, Banai S, Keren A, Tzivoni D. Ventricular ectopic activity during myocardial ischemic episodes in ambulatory patients. Am J Cardiol 1990; 65:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/19\">",
"      Larsen L, Markham J, Haffajee CI. Sudden death in idiopathic dilated cardiomyopathy: role of ventricular arrhythmias. Pacing Clin Electrophysiol 1993; 16:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/20\">",
"      Chakko CS, Gheorghiade M. Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. Am Heart J 1985; 109:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/21\">",
"      Podrid PJ, Fogel RI, Fuchs TT. Ventricular arrhythmia in congestive heart failure. Am J Cardiol 1992; 69:82G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/22\">",
"      Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984; 53:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/23\">",
"      Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation 2000; 101:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/24\">",
"      Singh SN, Fisher SG, Carson PE, Fletcher RD. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. J Am Coll Cardiol 1998; 32:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/25\">",
"      Le VV, Mitiku T, Hadley D, et al. Rest premature ventricular contractions on routine ECG and prognosis in heart failure patients. Ann Noninvasive Electrocardiol 2010; 15:56.",
"     </a>",
"    </li>",
"    <li>",
"     Kantor RJ, Garson A. Arrhythmias in Congenital Heart Disease. In: Cardiac Arrhythmia: Mechanisms, Diagnosis, and Management, Podrid PJ, Kowey PR (Eds), Williams &amp; Wilkins, Baltimore 1995. p.1131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/27\">",
"      Wolff GA, Veith F, Lown B. A vulnerable period for ventricular tachycardia following myocardial infarction. Cardiovasc Res 1968; 2:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/28\">",
"      de Soyza N, Bissett JK, Kane JJ, et al. Ectopic ventricular prematurity and its relationship to ventricular tachycardia in acute myocardial infarction in man. Circulation 1974; 50:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/29\">",
"      Roberts R, Ambos HD, Loh CW, Sobel BE. Initiation of repetitive ventricular depolarizations by relatively late premature complexes in patients with acute myocardial infarction. Am J Cardiol 1978; 41:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/30\">",
"      Morganroth J, Michelson EL, Horowitz LN, et al. Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency. Circulation 1978; 58:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/31\">",
"      Michelson EL, Morganroth J. Spontaneous variability of complex ventricular arrhythmias detected by long-term electrocardiographic recording. Circulation 1980; 61:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/32\">",
"      Raeder EA, Hohnloser SH, Graboys TB, et al. Spontaneous variability and circadian distribution of ectopic activity in patients with malignant ventricular arrhythmia. J Am Coll Cardiol 1988; 12:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/33\">",
"      Toivonen L. Spontaneous variability in the frequency of ventricular premature complexes over prolonged intervals and implications for antiarrhythmic treatment. Am J Cardiol 1987; 60:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/34\">",
"      Pratt CM, Slymen DJ, Wierman AM, et al. Analysis of the spontaneous variability of ventricular arrhythmias: consecutive ambulatory electrocardiographic recordings of ventricular tachycardia. Am J Cardiol 1985; 56:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/35\">",
"      Pratt CM, Delclos G, Wierman AM, et al. The changing base line of complex ventricular arrhythmias. A new consideration in assessing long-term antiarrhythmic drug therapy. N Engl J Med 1985; 313:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9320/abstract/36\">",
"      Lichstein E, Morganroth J, Harrist R, Hubble E. Effect of propranolol on ventricular arrhythmia. The beta-blocker heart attack trial experience. Circulation 1983; 67:I5.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 994 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9320=[""].join("\n");
var outline_f9_6_9320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3565692\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal individuals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypertension and LVH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4456148\">",
"      Chronic CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dilated cardiomyopathy and HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MECHANISMS FOR VPBS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9829334\">",
"      Reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Enhanced automaticity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Triggered activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3566020\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Parasystole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Multifocal VPBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      R on T phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bigeminy, trigeminy, and quadrigeminy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3566083\">",
"      - Ambulatory monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - EP testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3565692\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/994\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/994|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?25/6/25704\" title=\"waveform 1\">",
"      Ventric premature beat tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?24/63/25592\" title=\"waveform 2\">",
"      Interpolated VPB tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?14/38/14953\" title=\"waveform 3\">",
"      Ventricle parasystole tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/44/13002\" title=\"waveform 4\">",
"      Ventricular bigeminy tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/34/43559\" title=\"waveform 5\">",
"      Ventricular trigeminy tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=related_link\">",
"      ECG tutorial: Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=related_link\">",
"      Enhanced cardiac automaticity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/23/39281?source=related_link\">",
"      Patient information: Ventricular premature beats (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_6_9321="Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients";
var content_f9_6_9321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9321/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9321/contributors\">",
"     Joseph Wheat, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9321/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9321/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9321/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9321/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/6/9321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasmosis is a common endemic mycosis that is usually asymptomatic, but occasionally results in severe illness. Histoplasmosis and its causative agent, Histoplasma capsulatum, are found worldwide, but particularly in North and Central America. Within the United States, infection is most common in the midwestern states located in the Ohio and Mississippi River valleys. Among the endemic mycoses, it is the most common cause for hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disseminated histoplasmosis is a progressive extrapulmonary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/2\">",
"     2",
"    </a>",
"    ]. Hematogenous dissemination probably occurs in most patients during the acute infection before cellular immunity develops. Disseminated disease occurs in approximately 1 in 2000 patients with acute infection. Most patients who develop disseminated histoplasmosis are immunosuppressed (eg, AIDS, solid organ transplantation, treatment with tumor necrosis factor-alpha inhibitors) or are at the extremes of age. In addition, chronic progressive disseminated histoplasmosis occurs rarely in older adults with no known immunosuppressing conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of disseminated histoplasmosis requires a high index of suspicion, recognition of the common modes of presentation, and familiarity with the appropriate diagnostic tests. Treatment is highly effective but relapse can occur in severely immunocompromised individuals.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of disseminated histoplasmosis will be reviewed here. The pathogenesis, risk factors for dissemination, and clinical manifestations of this infection and the diagnosis and treatment of localized pulmonary histoplasmosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of disseminated histoplasmosis are fever, fatigue, and weight loss. Symptoms and signs may point to involvement of specific sites, such as the skin, oropharynx, gastrointestinal tract, central nervous system (CNS), and adrenal glands. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis in such patients includes malignancy, infection (eg, tuberculosis, other fungal diseases), or inflammatory disease (eg, inflammatory bowel disease, sarcoidosis). Misdiagnosis of an inflammatory process may lead to inappropriate and harmful therapy with glucocorticoids, cytotoxic agents, or tumor necrosis factor-alpha inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\", section on 'Distinction from sarcoidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVIDENCE FOR DISSEMINATED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression is a strong risk factor for dissemination in patients with histoplasmosis. Microscopic demonstration or isolation of Histoplasma from extrapulmonary sites provides proof of dissemination in patients with histoplasmosis. In cases in which results are negative or specimens were not tested, other findings may suggest that dissemination is present. A variety of clinical, radiographic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory abnormalities may give a clue as to the sites of involvement in disseminated histoplasmosis, as noted below: [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/3\">",
"     3",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral lymphadenopathy, hepatomegaly, splenomegaly, skin lesions, mucosal lesions, altered mental status, or neurologic abnormalities. &nbsp;",
"     </li>",
"     <li>",
"      Anemia, leukopenia, and thrombocytopenia, suggesting bone marrow or spleen involvement (",
"      <a class=\"graphic graphic_picture graphicRef57613 \" href=\"UTD.htm?7/22/7523\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Elevations in serum aminotransferases, alkaline phosphatase,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bilirubin, suggesting hepatic involvement. &nbsp;",
"     </li>",
"     <li>",
"      Markedly elevated serum lactate dehydrogenase and ferritin values.",
"     </li>",
"     <li>",
"      Interstitial or reticulonodular infiltrates &ndash; Chest radiographs are abnormal in 70 percent of patients, usually showing diffuse interstitial or reticulonodular infiltrates (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53565 \" href=\"UTD.htm?24/52/25408\">",
"       image 1",
"      </a>",
"      ); mediastinal adenopathy occurs in about 20 percent and cavitation is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. In one series of patients with disseminated histoplasmosis, the radiographic findings were diffuse in 24 percent, localized in 20 percent, miliary in 14 percent, and cavitary in 3 percent; 29 percent were normal [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/5\">",
"       5",
"      </a>",
"      ]. While diffuse infiltrates are also seen in patients with acute histoplasmosis following a large inoculum exposure, in the absence of such an exposure history, and especially in an immunosuppressed patient, diffuse reticulonodular or miliary infiltrates suggest disseminated disease.",
"     </li>",
"     <li>",
"      Cerebrospinal fluid (CSF) findings of lymphocytic pleocytosis, elevated protein, and low glucose concentration.",
"     </li>",
"     <li>",
"      Single or multiple enhancing brain lesions on computed tomography (CT) scan or magnetic resonance imaging (MRI). These can be seen in approximately one-third of patients with central nervous system (CNS) histoplasmosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70552 \" href=\"UTD.htm?16/46/17120\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abdominal CT scan showing enlargement of the liver, spleen, adrenal glands, or lymph nodes.",
"     </li>",
"     <li>",
"      Lesions in the stomach, small intestines, or colon found on gastrointestinal endoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF HISTOPLASMOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathology using stains for fungi, cultures, antigen detection, and serologic tests for Histoplasma-specific antibodies can all help one make the diagnosis of disseminated histoplasmosis. Rapid diagnosis is often achieved by antigen determination; cytologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histopathologic examination of tissue samples, respiratory secretions, or body fluids; or Wright&rsquo;s stain of blood smears (",
"    <a class=\"graphic graphic_picture graphicRef57613 \" href=\"UTD.htm?7/22/7523\">",
"     picture 1",
"    </a>",
"    ). Serologic tests for antibody to H. capsulatum and culture of the organism are less rapid methods but can aid in confirming the diagnosis of disseminated histoplasmosis",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antigen testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests for antigen in urine and serum should be performed in all patients suspected of having disseminated histoplasmosis in order to achieve the highest sensitivity. Reports from the laboratory that established the enzyme immunoassay showed that Histoplasma antigen can be detected in the urine of approximately 75 percent of non-immunocompromised and 95 percent of immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/8\">",
"     8",
"    </a>",
"    ]. Antigen can be detected in the serum of close to 100 percent of cases, including some cases in which results in urine were negative [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, large prospective studies that have included a broad spectrum of hosts and diverse manifestations have not been performed. Thus, it should be noted that a negative antigen test does not rule out disseminated histoplasmosis. Antigen can also be detected in the cerebrospinal fluid (CSF) in most patients with central nervous involvement. &nbsp;Respiratory specimens obtained via bronchoscopy tested positive for antigen in 90 percent of patients with pulmonary involvement in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/11\">",
"     11",
"    </a>",
"    ]. Other tests have been developed using different antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"    <strong>",
"     Please note that one of the authors (LJW) is owner and Director of MiraVista Diagnostics, a reference laboratory that performs Histoplasma antigen testing.",
"    </strong>",
"   </p>",
"   <p>",
"    False-positive results occur in most patients with blastomycosis and less frequently with coccidioidomycosis, paracoccidioidomycosis, and penicilliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/3\">",
"     3",
"    </a>",
"    ]. False-positive results also have been noted in bronchoalveolar lavage fluid in patients with aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356433011\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of polymerase chain reaction (PCR) for diagnosis of histoplasmosis is uncertain. In one study, two of six culture-positive BALs and 7 of 11 other respiratory specimens were positive using a commercial laboratory-developed PCR, but comparison to microscopy was not reported, leaving open the question of whether PCR improves the sensitivity for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;In another report, PCR was positive only if organisms were seen by microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/16\">",
"     16",
"    </a>",
"    ]. Other studies have noted a sensitivity of only 8 to 11 percent in urine or BAL specimens that were positive for Histoplasma antigen, while results in CSF and serum were uniformly negative [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cytology and histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of a skin lesion, mucous membrane lesion, bone marrow, or other tissue can reveal the typical 2 to 4 micron yeast structures of H. capsulatum. Although the organism sometimes can be demonstrated by hematoxylin and eosin stain, it is better visualized using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    silver or periodic acid Schiff (PAS) stains. In one retrospective review, yeasts were seen using fungal stains in respiratory secretions in 86 percent, lung in 77 percent and bone marrow in 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Antibody tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests for anti-Histoplasma antibodies using the immunodiffusion and complement fixation methods are positive in about 70 percent of immunocompromised and 90 percent of immunocompetent patients with disseminated infection. Several studies have reported that antibody tests were positive in only 20 percent of patients who were taking tumor necrosis factor-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/9\">",
"     9",
"    </a>",
"    ], and 67 percent of patients who had undergone solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/19\">",
"     19",
"    </a>",
"    ]. Nevertheless, both the immunodiffusion test and the complement fixation test are recommended in evaluation of all patients with suspected histoplasmosis. An enzyme immunoassay has been used as a screening test, but may be falsely negative in patients who have positive immunodiffusion or complement fixation tests, and thus is not recommended.",
"   </p>",
"   <p>",
"    A comparison of serologic methods is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\", section on 'Comparison of serologic methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures should be performed in all suspected cases. Using the lysis-centrifugation technique, cultures are positive in about 65 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/18,20,21\">",
"     18,20,21",
"    </a>",
"    ]. Bone marrow aspiration and biopsy for fungal stains and culture should be performed in patients who are anemic, leukopenic, or thrombocytopenic. Histoplasma can also be isolated from other specimens. In patients with diffuse pulmonary infiltrates, H. capsulatum can be cultured from respiratory and lung tissue in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/18\">",
"     18",
"    </a>",
"    ]. Depending on the sites involved, biopsy of the mouth, skin, gastrointestinal tract lesions, lymph nodes, adrenal glands, or liver can yield the organism in culture [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the diagnosis of meningitis due to histoplasmosis is difficult. Among patients with isolated meningitis, the diagnosis may be based upon detection of antigen or antibody in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/7\">",
"     7",
"    </a>",
"    ]. Cultures of CSF are positive in about 50 percent of cases, but fungal stains are rarely positive.",
"   </p>",
"   <p>",
"    Large volumes of CSF (10 to 20 mL) should be cultured for fungus on at least two occasions to achieve the best diagnostic yield. If the results of large volume lumbar spinal taps are negative, the diagnosis of histoplasmosis is not excluded. Options in this setting include repeat lumbar puncture and cisternal aspiration. Shunt aspiration is the preferred approach in patients with ventriculoperitoneal shunts.",
"   </p>",
"   <p>",
"    Patients also may have positive cultures from blood or other tissues. At least three blood cultures for fungal organisms should be performed in all cases of suspected Histoplasma meningitis, and bone marrow cultures should be considered in patients with clinical evidence for generalized dissemination.",
"   </p>",
"   <p>",
"    In rare cases, all of the above tests are negative and meningeal or brain biopsy is needed to establish a diagnosis of meningeal or cerebral histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of untreated acute disseminated infection is progressive and fatal over a 2 to 12 week course compared to months to years with chronic illness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/2\">",
"     2",
"    </a>",
"    ]. Recurrent illness, separated by asymptomatic periods ranging from several years up to two decades, may be seen in patients with the chronic form of disseminated histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is indicated for all patients with disseminated histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/23\">",
"     23",
"    </a>",
"    ]. A variety of antifungal drugs have been tested in clinical trials.",
"   </p>",
"   <p>",
"    Clinical practice guidelines for the management of patients with histoplasmosis were updated in 2007 by the Infectious Diseases Society of America [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Selection of antifungal agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major choices for therapy are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , one of its lipid formulations, or an azole drug, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . The choice between these drugs depends upon disease severity (",
"    <a class=\"graphic graphic_table graphicRef57457 \" href=\"UTD.htm?15/53/16220\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the lipid formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      is recommended in patients who are sufficiently ill to require hospitalization.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      is not recommended for initial therapy in such patients because it does not eradicate fungemia as rapidly as amphotericin B [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      is the treatment of choice for patients who have mild to moderate symptoms and for step-down therapy in those who have improved with initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      administration [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      are less predictably effective, and ketoconazole is associated with a higher rate of side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of central nervous system (CNS) histoplasmosis is discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'CNS histoplasmosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lipid formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (eg, AmBisome or Abelcet) require doses of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/29\">",
"     29",
"    </a>",
"    ]. If the deoxycholate formulation (Fungizone) is used, a dose of 0.7 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized controlled trial showed that induction therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    produced better outcomes than the deoxycholate formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/29\">",
"     29",
"    </a>",
"    ]. Among 81 patients with AIDS and moderately severe to severe disseminated histoplasmosis, liposomal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    was associated with the following significant benefits: a higher rate of clinical success (88 versus 64 percent) despite similar rates of culture conversion, and lower rates of mortality (2 versus 13 percent), infusion related side effects (25 versus 63 percent), and nephrotoxicity (9 versus 37 percent).",
"   </p>",
"   <p>",
"    Although we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    , its use may be limited by cost and pharmacy restrictions. It should be noted that this preference is based on the results of only one study of a small number of patients.",
"   </p>",
"   <p>",
"    Most patients respond quickly to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and then can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . The transition from amphotericin B to itraconazole should occur after the patient becomes afebrile (or at least demonstrates consistent improvement in fever), no longer requires blood pressure or ventilatory support or intravenous fluids, and is able to take oral medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    capsules should be administered with food at a loading dose of 200 mg three times daily for three days to achieve steady-state serum concentrations more rapidly and then 200 mg once or twice daily, depending upon the concentrations achieved in the blood. Acid-blocking drugs should be avoided when the capsule formulation is given, and a cola beverage can be administered to increase gastric acidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The liquid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    overcomes problems caused by poor absorption of the capsule and achieves approximately 30 percent higher concentrations in the serum at the same dose. The solution should be given on an empty stomach to achieve the highest serum concentrations. However, more gastrointestinal upset occurs with the solution formulation, which precludes its use in some patients.",
"   </p>",
"   <p>",
"    Serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    concentrations should be measured after the second week of therapy, the time required for attainment of steady-state levels. The serum samples may be obtained independent of the time of administration because of the long half-life of the drug.",
"   </p>",
"   <p>",
"    The therapeutic serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    concentration range has not been defined. We have observed minimum inhibitory concentrations of H. capsulatum yeast phase organisms to be 0.01",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    or below, suggesting that serum concentrations of at least 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    by HPLC and at least 3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    by bioassay are adequate. The bioassay values are generally three times higher than those obtained by HPLC methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"     \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications to repeat serum measurements include initially low values, dose modification, concern about compliance or absorption, initiation of treatment with potentially interacting medications, and suspicion of relapse.",
"   </p>",
"   <p>",
"    The optimal duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    therapy is not known. Therapy for at least one year is preferred, because it may reduce the risk for relapse. Chronic maintenance therapy may be needed in immunosuppressed individuals and those who relapse after one year of treatment.",
"   </p>",
"   <p>",
"    Because adrenal insufficiency associated with disseminated histoplasmosis is usually irreversible, maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    therapy is required life-long and patients must be warned about the dangers inherent in stopping this replacement therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is not as active in vitro against H. capsulatum as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and has not been as effective when used for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] in part because fungemia is cleared more slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/30\">",
"     30",
"    </a>",
"    ]. In one study, 75 percent of patients with AIDS who had mild or moderately severe disease responded to fluconazole (800",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    however, nearly one-third relapsed while receiving 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as chronic maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another problem with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is the development of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/31\">",
"     31",
"    </a>",
"    ]. In one report, one-half of Histoplasma strains from patients with AIDS who failed fluconazole therapy had developed in vitro resistance to the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    should be reserved for treatment of histoplasmosis in patients who cannot take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . The fluconazole dose should be at least 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in immunocompetent individuals and 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in those with AIDS or other severe immunocompromising conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several newer drugs exhibit in vitro activity against H. capsulatum, but none has been evaluated fully:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H. capsulatum is highly susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      , which was effective as salvage therapy in a few patients who failed other regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      is less active than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/33\">",
"       33",
"      </a>",
"      ], but has been used successfully in a small number of patients with disseminated histoplasmosis who failed or could not tolerate other therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      H. capsulatum is not susceptible to the echinocandins [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;All azoles are associated with a variety of drug interactions that may influence the choice of medication or dosing. These include drugs that can accelerate or impair the metabolism of an azole agent and drugs whose metabolism is slowed by the azoles. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?33/17/34069?source=see_link\">",
"     \"Itraconazole: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?29/4/29765?source=see_link\">",
"     \"Fluconazole: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Monitoring response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasma antigen concentrations in the urine and serum fall with effective therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/37\">",
"     37",
"    </a>",
"    ]. The absence of this response after at least three months of therapy suggests that treatment may not be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Responders should be monitored with serum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine antigen testing being performed at four to six month intervals (",
"    <a class=\"graphic graphic_algorithm graphicRef64801 \" href=\"UTD.htm?42/38/43619\">",
"     algorithm 1",
"    </a>",
"    ). A rise of 3",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    raises concern for relapse or treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     CNS histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for Histoplasma meningitis is difficult because of the poor penetration of most antifungal agents into the cerebrospinal fluid (CSF). Only 60 to 80 percent of patients with meningitis respond to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and up to one-half of responders relapse during subsequent years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/7\">",
"     7",
"    </a>",
"    ]. Aggressive therapy is recommended to achieve the greatest chance for a successful outcome. A clinician with experience in managing patients with CNS histoplasmosis should be consulted.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     Liposomal amphotericin B",
"    </a>",
"    (AmBisome) achieves higher concentrations in the blood and brain than other lipid formulations or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate, providing a theoretical basis for its use in CNS histoplasmosis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    achieves excellent concentrations in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/38\">",
"     38",
"    </a>",
"    ]. Despite this apparent advantage, fluconazole was less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    as monotherapy and fluconazole plus amphotericin B was less effective than amphotericin B alone in an experimental model of Histoplasma meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/39\">",
"     39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    , although more active than fluconazole against H. capsulatum, does not achieve measurable concentrations in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/40\">",
"     40",
"    </a>",
"    ]. However, this agent has been used successfully in the treatment of Histoplasma meningitis, as well as other fungal meningitides.",
"   </p>",
"   <p>",
"    We recommend the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (AmBisome, 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily for four to six weeks). A similar dose and duration of therapy is recommended if the lipid complex formulation (Abelcet) is used. Dose reduction or earlier transition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    may be needed in patients who develop renal impairment while taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Following induction therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (400 to 600 mg orally daily) should be given for at least one year to prevent relapse. In patients unable to tolerate itraconazole, high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is an alternative.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    also may have a role in maintenance therapy, but supporting clinical data are limited.",
"   </p>",
"   <p>",
"    Consultation with an expert should be considered if alternative therapy is contemplated. Some clinicians will treat for life, rather than stopping after one year, because of the risk of relapse.",
"   </p>",
"   <p>",
"    Patients with CNS histoplasmosis should be followed closely for relapse of infection. Testing should include Histoplasma antigen from the serum and urine as well as the following CSF studies: protein, glucose, white blood cell count, culture, and Histoplasma antigen.",
"   </p>",
"   <p>",
"    Measurement of blood concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    early in the course of therapy is recommended to ensure adequate serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Itraconazole'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Relapse despite chronic suppressive therapy is an indication for repeat treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    . Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    directly into the ventricles, cisterna magna, or lumbar arachnoid space is rarely indicated and evidence is lacking for its effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H895771044\">",
"    <span class=\"h2\">",
"     Suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term or sometimes life-long suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    may be necessary in patients who are at risk for relapse of histoplasmosis because their immunosuppression cannot be reversed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9321/abstract/9,34\">",
"     9,34",
"    </a>",
"    ]. &nbsp;Generally, itraconazole is continued at a dosage of 200 mg once or twice daily for patients requiring suppressive therapy. &nbsp;",
"   </p>",
"   <p>",
"    <br/>",
"    Suppressive therapy in HIV-infected patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1449?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnosis and treatment of histoplasmosis in HIV-infected patients\", section on 'Suppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/5/13393?source=see_link\">",
"       \"Patient information: Histoplasmosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histoplasmosis is the most prevalent endemic mycosis in the United States. Most infections are asymptomatic or self-limited, but some individuals develop acute pulmonary infection or severe and progressive disseminated disease. Most patients who develop disseminated histoplasmosis are immunosuppressed or are at the extremes of age. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptoms of disseminated histoplasmosis are fever, fatigue, and weight loss. Symptoms and signs may point to involvement of specific sites, such as the oropharynx, respiratory tract, gastrointestinal tract, central nervous system (CNS), or adrenal glands. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes malignancy, infection (eg, tuberculosis, other fungal diseases), and inflammatory diseases (eg, inflammatory bowel disease, sarcoidosis). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiographs are abnormal in about 70 percent of patients, usually showing diffuse interstitial or reticulonodular infiltrates (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53565 \" href=\"UTD.htm?24/52/25408\">",
"       image 1",
"      </a>",
"      ); mediastinal adenopathy occurs in about 20 percent while cavitation is rare. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evidence for disseminated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests for antigen in urine and serum should be performed in patients with suspected disseminated histoplasmosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antigen testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood cultures should be performed in all suspected cases. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibody assays are useful in the diagnosis of the chronic forms of disseminated histoplasmosis but may be negative in acutely ill patients and in those who are immunosuppressed.",
"     </li>",
"     <li>",
"      Establishing the diagnosis of meningitis due to histoplasmosis is difficult (",
"      <a class=\"graphic graphic_table graphicRef50806 \" href=\"UTD.htm?19/21/19804\">",
"       table 2",
"      </a>",
"      ). Among patients who have isolated meningitis, the diagnosis may be based upon detection of antigen or antibody in the cerebrospinal fluid (CSF). &nbsp;(See",
"      <a class=\"local\" href=\"#H9\">",
"       'Meningitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of untreated acute disseminated infection is progressive and fatal over a 2 to 12 week course compared to months to years with chronic disseminated histoplasmosis. Treatment is indicated for all patients with disseminated histoplasmosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major choices for therapy are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , one of its lipid formulations, or an azole drug, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      . The choice between these drugs depends upon disease severity (",
"      <a class=\"graphic graphic_table graphicRef57457 \" href=\"UTD.htm?15/53/16220\">",
"       table 1",
"      </a>",
"      ). Summarized briefly:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One of the lipid formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      is recommended in patients who are sufficiently ill to require hospitalization.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      is not recommended for initial therapy in such patients since it does not eradicate fungemia as rapidly as amphotericin.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      is the treatment of choice for patients who have mild to moderate symptoms and for step-down therapy in those who have improved with initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      administration. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Selection of antifungal agent'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lipid formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (eg, AmBisome or Abelcet) require doses of 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily. If the deoxycholate formulation is used, a dose of 0.7 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily is recommended.",
"     </li>",
"     <li>",
"      Most patients respond quickly to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      and then can be transitioned to oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      . The transition should occur after the patient becomes afebrile (or at least demonstrates consistent improvement in fever), no longer requires blood pressure or ventilatory support or intravenous fluids, and is able to take oral medications. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Amphotericin B'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For CNS histoplasmosis, we recommend the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (AmBisome, 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily for four to six weeks). A similar dose and duration of therapy is recommended if the lipid complex formulation (Abelcet) is used. Following induction therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg orally twice or three times daily) should be given for at least one year to prevent relapse. In patients unable to tolerate itraconazole, high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      is an alternative. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'CNS histoplasmosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/1\">",
"      Chu JH, Feudtner C, Heydon K, et al. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 2006; 42:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/2\">",
"      Goodwin RA Jr, Shapiro JL, Thurman GH, et al. Disseminated histoplasmosis: clinical and pathologic correlations. Medicine (Baltimore) 1980; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/3\">",
"      Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther 2006; 6:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/4\">",
"      Sathapatayavongs B, Batteiger BE, Wheat J, et al. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983; 62:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/5\">",
"      Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990; 69:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/6\">",
"      Conces DJ Jr, Stockberger SM, Tarver RD, Wheat LJ. Disseminated histoplasmosis in AIDS: findings on chest radiographs. AJR Am J Roentgenol 1993; 160:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/7\">",
"      Wheat LJ, Batteiger BE, Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system. A clinical review. Medicine (Baltimore) 1990; 69:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/8\">",
"      Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis 2011; 53:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/9\">",
"      Hage CA, Bowyer S, Tarvin SE, et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 2010; 50:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/10\">",
"      Connolly PA, Durkin MM, Lemonte AM, et al. Detection of histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol 2007; 14:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/11\">",
"      Hage CA, Davis TE, Fuller D, et al. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest 2010; 137:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/12\">",
"      Scheel CM, Samayoa B, Herrera A, et al. Development and evaluation of an enzyme-linked immunosorbent assay to detect Histoplasma capsulatum antigenuria in immunocompromised patients. Clin Vaccine Immunol 2009; 16:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/13\">",
"      Lindsley MD, Holland HL, Bragg SL, et al. Production and evaluation of reagents for detection of Histoplasma capsulatum antigenuria by enzyme immunoassay. Clin Vaccine Immunol 2007; 14:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/14\">",
"      Cloud JL, Bauman SK, Neary BP, et al. Performance characteristics of a polyclonal enzyme immunoassay for the quantitation of Histoplasma antigen in human urine samples. Am J Clin Pathol 2007; 128:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/15\">",
"      Babady NE, Buckwalter SP, Hall L, et al. Detection of Blastomyces dermatitidis and Histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR. J Clin Microbiol 2011; 49:3204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/16\">",
"      Bialek R, Cirera AC, Herrmann T, et al. Nested PCR assays for detection of Blastomyces dermatitidis DNA in paraffin-embedded canine tissue. J Clin Microbiol 2003; 41:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/17\">",
"      Tang YW, Li H, Durkin MM, et al. Urine polymerase chain reaction is not as sensitive as urine antigen for the diagnosis of disseminated histoplasmosis. Diagn Microbiol Infect Dis 2006; 54:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/18\">",
"      Assi MA, Sandid MS, Baddour LM, et al. Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients. Medicine (Baltimore) 2007; 86:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/19\">",
"      Cuellar-Rodriguez J, Avery RK, Lard M, et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis 2009; 49:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/20\">",
"      Fuller DD, Davis TE Jr, Denys GA, York MK. Evaluation of BACTEC MYCO/F Lytic medium for recovery of mycobacteria, fungi, and bacteria from blood. J Clin Microbiol 2001; 39:2933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/21\">",
"      Lyon R, Woods G. Comparison of the BacT/Alert and Isolator blood culture systems for recovery of fungi. Am J Clin Pathol 1995; 103:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/22\">",
"      Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 2005; 40:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/23\">",
"      Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/24\">",
"      Wheat LJ, Cloud G, Johnson PC, et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother 2001; 45:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/25\">",
"      Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995; 98:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/26\">",
"      Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992; 93:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/27\">",
"      Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997; 103:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/28\">",
"      McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1996; 23:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/29\">",
"      Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/30\">",
"      Wheat LJ, Connolly P, Haddad N, et al. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrob Agents Chemother 2002; 46:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/31\">",
"      Wheat LJ, Connolly P, Smedema M, et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001; 33:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/32\">",
"      Restrepo A, Tob&oacute;n A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/33\">",
"      Wheat LJ, Connolly P, Smedema M, et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 2006; 57:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/34\">",
"      Freifeld AG, Iwen PC, Lesiak BL, et al. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis 2005; 7:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/35\">",
"      Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009; 53:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/36\">",
"      Hage CA, Connolly P, Horan D, et al. Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum. Antimicrob Agents Chemother 2011; 55:4447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/37\">",
"      Hage CA, Kirsch EJ, Stump TE, et al. Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay. Clin Vaccine Immunol 2011; 18:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/38\">",
"      Tucker RM, Williams PL, Arathoon EG, et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother 1988; 32:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/39\">",
"      Haynes RR, Connolly PA, Durkin MM, et al. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis 2002; 185:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9321/abstract/40\">",
"      de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992; 6:185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2461 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-80C555DD96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9321=[""].join("\n");
var outline_f9_6_9321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVIDENCE FOR DISSEMINATED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS OF HISTOPLASMOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antigen testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356433011\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cytology and histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Antibody tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Selection of antifungal agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Monitoring response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CNS histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H895771044\">",
"      Suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2461|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/38/43619\" title=\"algorithm 1\">",
"      Follow-up testing in histo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2461|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/52/25408\" title=\"diagnostic image 1\">",
"      Miliary infiltrates in histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/46/17120\" title=\"diagnostic image 2\">",
"      CNS histoplasmosis MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2461|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/22/7523\" title=\"picture 1\">",
"      Histoplasma blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/53/16220\" title=\"table 1\">",
"      Disseminated histo rx recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/21/19804\" title=\"table 2\">",
"      Histoplasma meningitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1449?source=related_link\">",
"      Diagnosis and treatment of histoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/4/29765?source=related_link\">",
"      Fluconazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/17/34069?source=related_link\">",
"      Itraconazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=related_link\">",
"      Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/5/13393?source=related_link\">",
"      Patient information: Histoplasmosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_6_9322="Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors";
var content_f9_6_9322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9322/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9322/contributors\">",
"     Mario E Lacouture, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9322/contributors\">",
"     Yevgeniy Balagula, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9322/contributors\">",
"     Maja Mockenhaupt, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/6/9322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/6/9322/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/6/9322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H195039099\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents targeting the epidermal growth factor (EGFR)-mediated signalling pathway are increasingly used for the treatment of advanced lung, pancreatic, colorectal, and head and neck cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. They include monoclonal antibodies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    ) and small-molecule tyrosine kinase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    ). The ability of EGFR inhibitors to block specific molecular pathways driving uncontrolled cellular division in cancer has resulted in a decreased incidence of serious systemic adverse events commonly associated with conventional cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/3\">",
"     3",
"    </a>",
"    ]. However, cutaneous adverse events to EGFR inhibitors are frequent, due to the abundant expression of EGFR in the skin and adnexal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/4\">",
"     4",
"    </a>",
"    ]. Cutaneous adverse reactions to EGFR inhibitors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acneiform (papulopustular) rash",
"     </li>",
"     <li>",
"      Abnormal scalp, facial hair,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eyelash growth",
"     </li>",
"     <li>",
"      Paronychia with or without pyogenic granulomas",
"     </li>",
"     <li>",
"      Telangiectasias",
"     </li>",
"     <li>",
"      Xerosis and pruritus",
"     </li>",
"     <li>",
"      Xerotic dermatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acneiform eruption is the prototypical cutaneous adverse reaction associated with all EGFR inhibitors. Acneiform eruption is rarely life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/5\">",
"     5",
"    </a>",
"    ]. However, it affects cosmetically sensitive areas, causes pain and pruritus, and may impair the patient&rsquo;s quality of life and adherence to cancer therapies. In intolerable or severe cases, dose modification or interruption of a potentially life-prolonging therapy may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acneiform eruption secondary to EGFR inhibitors will be reviewed in this topic. Other cutaneous adverse reactions to molecularly targeted therapy or conventional chemotherapy agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=see_link\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039106\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acneiform eruptions occur in over 80 percent of patients treated with EGFR inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients of any age may be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3612236\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential risk factors for the development of EGFR inhibitor-related acneiform rash include age, sex, skin phototype, UV exposure, smoking, and combination therapy with conventional chemotherapy agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with advanced non-small cell lung cancer treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      , age &ge;70 is associated with an increased risk of severe (grade &ge;3 (",
"      <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"       table 1",
"      </a>",
"      )) rash [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/8\">",
"       8",
"      </a>",
"      ]. In contrast, in patients with metastatic colorectal cancer treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      , age &le;70 and male sex are associated with a higher rate of grade 3 eruption [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      , grade 3 to 4 rash (",
"      <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"       table 1",
"      </a>",
"      ) occurred almost exclusively in patients with skin phototype",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The frequent localization of the acneiform eruption to sun-exposed areas such as the face and the &ldquo;V&rdquo; area of the neck and upper chest suggests that UV radiation may act as a cofactor in the development or severity of skin eruption. Pre-clinical data also implicate an EGFR as an important mediator of keratinocyte proliferation and survival in response to exposure UV light.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inhibition of EFGR in cultured keratinocytes prior to UVR exposure has been shown to decrease cell survival and enhance",
"    <span class=\"nowrap\">",
"     apoptosis/necrosis",
"    </span>",
"    following UV irradiation, compared with cells exposed only to UV radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/11\">",
"     11",
"    </a>",
"    ]. However, in a randomized trial, the daily application of a sunscreen with a sun protection factor of 60 did not prevent or reduce the severity of the skin reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/12\">",
"     12",
"    </a>",
"    ]. Nonetheless, sunscreen is recommended because of the potential photosensitivity related to EGFR inhibitors. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with non-small cell lung cancer, smoking during therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      is associated with a lower incidence of skin eruption [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/13\">",
"       13",
"      </a>",
"      ]. A possible mechanism is the induction of the liver cytochrome P450 3A4 with subsequent enhanced clearance of the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. This mechanism is supported by the observation that the maximum tolerated dose of erlotinib is increased among active smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of nine trials (5333 patients), the incidence of grade &ge;3 rash (",
"      <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"       table 1",
"      </a>",
"      ) was higher in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      in combination with a variety of conventional cytotoxic agents than in patients treated with cetuximab alone [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31702946\">",
"    <span class=\"h2\">",
"     Relationship between rash and survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have noted an association between acneiform eruption and increased overall response rate or survival, suggesting that the skin eruption may be a surrogate marker for efficacy of EGFR inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. In a meta-analysis of 24 trials (3312 patients) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    for non-small cell lung cancer, patients who developed a rash had a lower risk of death than patients without rash (hazard ratio [HR] 0.30; 95% CI 0.21&ndash;0.43) and disease progression (HR 0.50; 95% CI 0.41&ndash;0.61) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, in a small randomized trial, dose escalation of EGFR inhibitors in patients with grade &le;1 rash was associated with an increased response rate to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/24\">",
"     24",
"    </a>",
"    ]. Although the strategy for dose escalation based upon the rash grade (&ldquo;dosing-to-rash&rdquo;) requires further study before it can be routinely recommended, these observations suggest that acneiform eruption is",
"    <strong>",
"     not",
"    </strong>",
"    a contraindication to continued EGFR inhibitor therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039113\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct inhibition of the EGFR and induction of an inflammatory response are critical steps in the development of the primary lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039120\">",
"    <span class=\"h2\">",
"     Direct receptor inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the epidermis, the EGFR is preferentially expressed in undifferentiated, actively proliferating basal and suprabasal keratinocytes, outer layers of the hair follicle, and pilosebaceous glands [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Coupled to various intracellular signaling pathways, EGFR plays a critical role in maintaining epidermal homeostasis through regulation of keratinocyte proliferation, differentiation, migration, and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/28\">",
"     28",
"    </a>",
"    ]. The intracellular signaling pathways may include RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)-AKT, stress-activated protein kinase, and",
"    <span class=\"nowrap\">",
"     JAK/STAT.",
"    </span>",
"   </p>",
"   <p>",
"    Direct",
"    receptor inhibition by tyrosine kinase inhibitors or monoclonal antibodies downregulates the level of the phosphorylated EGFR in basal and suprabasal keratinocytes and the outer layer of hair follicles resulting in [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diminished proliferation of basal keratinocytes evidenced by the reduced expression of the proliferation marker Ki67 and increased expression of the negative growth regulator p27",
"     </li>",
"     <li>",
"      Growth arrest and apoptosis of keratinocytes",
"     </li>",
"     <li>",
"      Increased expression of terminal differentiation markers keratin 1 and STAT3 in the basal keratinocytes reflecting premature and accelerated differentiation",
"     </li>",
"     <li>",
"      Decreased migration of differentiating keratinocytes through the epidermis due to enhanced cell attachment mediated by increased expression of desmoglein 2",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039127\">",
"    <span class=\"h2\">",
"     Inflammatory response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure of epithelial cells to EGFR inhibitors induces upregulation of IL-1 and TNF-alpha and increased synthesis of other inflammatory chemokines and cytokines (eg, monocyte chemoattractant protein 1 (CCL-2), RANTES (CCL-5), T-lymphocyte-recruiting CCL-18, CCL-3), resulting in the formation of an early infiltrate of CD45RO",
"    <sup>",
"     +",
"    </sup>",
"    T lymphocytes, Langerhans cells, macrophages, and tumor necrosis factor related apoptosis inducing ligand (TRAIL)-positive cells with dendritic morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/25,29,34,35\">",
"     25,29,34,35",
"    </a>",
"    ]. The eventual influx of neutrophils contributes to the inflammation manifesting as superficial perifolliculitis or suppurative folliculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/29,35\">",
"     29,35",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The inflammatory response also may be secondary to altered growth and differentiation of follicular epithelium, which results in keratotic plugging and rupture of follicular infundibulum and influx of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/35\">",
"     35",
"    </a>",
"    ]. This theory is supported by the observation that abnormal pilosebaceous units are present in both affected and unaffected skin of patients exposed to EGFR inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/34\">",
"     34",
"    </a>",
"    ]. In mouse models, an initial alteration in hair follicles and pilosebaceous units is followed by inflammatory changes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039134\">",
"    <span class=\"h2\">",
"     Role of microorganisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microorganisms do not appear to contribute to the pathogenesis of the early eruption and the initial pustule is sterile [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/35\">",
"     35",
"    </a>",
"    ]. However, secondary infection with",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    may have a role in the late phase of the rash, sometimes after several months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3612515\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently affected structures include hair follicles (61 percent), epidermis (52 percent), and sebaceous glands (45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/34\">",
"     34",
"    </a>",
"    ]. The two major histopathologic patterns are a superficial perifolliculitis, characterized by neutrophilic infiltrate surrounding the hyperkeratotic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ectatic follicular infundibula, and a florid neutrophilic suppurative folliculitis with rupture of the epithelial lining [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stratum corneum is compact and eosinophilic and its normal basket-weave appearance is lost [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/30,39\">",
"     30,39",
"    </a>",
"    ]. Epidermal atrophy, keratinocyte dysmaturation, and dyskeratosis may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/40\">",
"     40",
"    </a>",
"    ]. Other reported alterations include intraepidermal acantholysis, vacuolar degeneration of the basal cell layer, prominent keratin plugs, and lichenoid changes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/30,35\">",
"     30,35",
"    </a>",
"    ]. The sebaceous glands are hypoplastic with poorly differentiated sebocytes and keratinocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/34\">",
"     34",
"    </a>",
"    ]. The histologic alterations of the pilosebaceous units without an inflammatory infiltrate also can be seen in uninvolved skin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039141\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary lesion of the EGFR inhibitor-induced acneiform eruption is a folliculocentric erythematous papule or pustule. Areas rich in sebaceous glands, such as the scalp, face, and particularly the nose, cheeks, nasolabial folds, and perioral region, are most commonly affected (",
"    <a class=\"graphic graphic_picture graphicRef55753 \" href=\"UTD.htm?21/20/21827\">",
"     picture 1",
"    </a>",
"    ). The upper trunk and especially the &ldquo;V&rdquo; region of the neck and chest also are involved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/35,41\">",
"     35,41",
"    </a>",
"    ]. Less frequently, the eruption may extend to the lower trunk, buttocks, and extremities. The palmoplantar surfaces are characteristically spared [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/4\">",
"     4",
"    </a>",
"    ]. Common associated symptoms include pruritus, pain, irritation, and stinging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of the eruption typically occurs within the first two weeks of therapy but it can occur up to two months after starting the treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The combination of EGFR inhibitors with other treatment modalities (eg, conventional cytotoxic chemotherapy agents, radiotherapy) may increase the severity of the acneiform eruption [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3611686\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acneiform eruption generally evolves through four distinct phases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First week &ndash;",
"      <strong>",
"      </strong>",
"      Sensory disturbance (dysesthesia) accompanied by erythema and edema &nbsp;",
"     </li>",
"     <li>",
"      First to third week &ndash;",
"      <strong>",
"      </strong>",
"      Development of erythematous papules and pustules",
"     </li>",
"     <li>",
"      Third to fourth week &ndash;",
"      <strong>",
"      </strong>",
"      Formation of crusts from purulent material and necrotic",
"      <span class=\"nowrap\">",
"       keratinocytes/debris",
"      </span>",
"     </li>",
"     <li>",
"      One month and longer &ndash;",
"      <strong>",
"      </strong>",
"      Persistent erythema with scattered telangiectasias and skin dryness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical course is characterized by waxing and waning of lesions. Partial or even complete resolution may be seen despite continued EGFR inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/43,46,47\">",
"     43,46,47",
"    </a>",
"    ]. Following the discontinuation of the offending agent, resolution typically occurs in four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699849676\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND SEQUELAE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699849684\">",
"    <span class=\"h2\">",
"     Secondary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the initial pustules are sterile, secondary infection of the affected skin may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/35\">",
"     35",
"    </a>",
"    ]. A retrospective analysis of 221 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    found that 38 percent developed infections with bacteria, dermatophytes, or viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    was isolated from approximately 60 percent of infected lesions. Staphylococcal bacteremia has been reported in patients with severe skin toxicity induced by erlotinib [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699849441\">",
"    <span class=\"h2\">",
"     Cutaneous sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term cutaneous sequelae of EGFR inhibitor-induced acneiform rash include postinflammatory hyperpigmentation, telangiectasias, and erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postinflammatory hyperpigmentation is typically a late adverse event, manifesting after several months of treatment. Postinflammatory hyperpigmentation occurs most often in patients with dark skin phototypes (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 2",
"    </a>",
"    ) and can be exacerbated by excessive UV radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/53\">",
"     53",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    4% cream may be used in an attempt to diminish the degree of hyperpigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dilated superficial capillaries and erythema may be observed in areas previously affected by the acneiform eruption one to two months after treatment. The initiating event in the development of telangiectasias could be the loss of structural support secondary to connective tissue destruction or the proliferation of endothelial cells in areas of keratinocyte necrosis that are present in follicular pustules [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/25\">",
"     25",
"    </a>",
"    ]. Pulsed dye laser and intense pulsed light may be utilized to treat telangiectasias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H10061370#H10061370\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Telangiectasias and the red face'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699849637\">",
"    <span class=\"h2\">",
"     Impact on patients&rsquo; quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms such as pain, pruritus, burning, and irritation are observed in approximately 60 percent of patients with EGFR inhibitor-induced acneiform eruption and can negatively affect the quality of life (QoL) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/48,54\">",
"     48,54",
"    </a>",
"    ]. A retrospective study examined the data from 67 patients who had completed the Skindex-16 (a self-reported, dermatology-specific QoL questionnaire) at the time of their initial visit for skin reaction to EGFR inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/42\">",
"     42",
"    </a>",
"    ]. A positive correlation was found between rash severity and median scores for symptoms, emotions, and function, with the highest score reported for the emotions domain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039162\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3612688\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acneiform eruption in patients receiving EGFR inhibitor therapy is usually straightforward, based upon the morphology and distribution of the rash (eg, erythematous follicular papules and pustules in areas rich in sebaceous glands) (",
"    <a class=\"graphic graphic_picture graphicRef55753 \" href=\"UTD.htm?21/20/21827\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039171\">",
"    <span class=\"h2\">",
"     Grading of severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not always performed in clinical practice, grading the severity of the acneiform eruption is important in guiding the approach to management. In clinical trials and in some oncology practices, the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) is the most commonly employed scale to assess the severity of cutaneous adverse reactions to cancer treatment (",
"    <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, the CTCAE scale, which is based upon the body surface area involvement and symptoms, may not capture specific features of the acneiform rash (eg, involvement of cosmetically sensitive areas,",
"    <span class=\"nowrap\">",
"     subacute/chronic",
"    </span>",
"    course) and does not incorporate the patient&rsquo;s perception of severity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039178\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of EGFR inhibitor-induced acneiform eruption includes acneiform eruptions induced by other drugs and other uncommon papulopustular eruptions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Drug-induced acne",
"      </strong>",
"      &ndash; Drug-induced acne typically presents with a monomorphous inflammatory papular eruption involving the trunk (",
"      <a class=\"graphic graphic_picture graphicRef86994 graphicRef86995 \" href=\"UTD.htm?6/8/6282\">",
"       picture 2A-B",
"      </a>",
"      ). Medications associated with drug-induced acne are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef76762 \" href=\"UTD.htm?11/32/11787\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=see_link&amp;anchor=H28#H28\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\", section on 'Drug-induced acne'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other chemotherapy agents associated with an acneiform eruption include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inhibitors of mammalian target of rapamycin (mTOR) &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"     </li>",
"     <li>",
"      Multikinase inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      &nbsp;",
"     </li>",
"     <li>",
"      MEK",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      inhibitor selumetinib (AZD6244, ARRY-142886)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pityrosporum folliculitis",
"      </strong>",
"      &ndash; Pityrosporum folliculitis is a skin infection caused by yeasts of the genus",
"      <em>",
"       Malassezia",
"      </em>",
"      and characterized by a monomorphous eruption of papules and pustules on the upper trunk or arms (",
"      <a class=\"graphic graphic_picture graphicRef86998 graphicRef86997 \" href=\"UTD.htm?8/20/8522\">",
"       picture 3A-B",
"      </a>",
"      ). Characteristic budding yeasts are detected on histologic examination of a skin biopsy after treatment with potassium hydroxide. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6021?source=see_link&amp;anchor=H6#H6\">",
"       \"Malassezia infection\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tinea barbae",
"      </strong>",
"      &ndash; Tinea (sycosis) barbae is a skin infection caused by dermatophytes of the genus",
"      <em>",
"       Trichophyton",
"      </em>",
"      occurring predominantly in men. The superficial type presents with papules and pustules in the beard and mustache area (",
"      <a class=\"graphic graphic_picture graphicRef86999 graphicRef87000 \" href=\"UTD.htm?0/12/202\">",
"       picture 4A-B",
"      </a>",
"      ). A potassium hydroxide preparation shows the segmented hyphae and arthrospores characteristic of dermatophyte infections (",
"      <a class=\"graphic graphic_picture graphicRef60102 \" href=\"UTD.htm?4/2/4132\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"       \"Dermatophyte (tinea) infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Eosinophilic folliculitis",
"      </strong>",
"      &ndash; Eosinophilic folliculitis is a pruritic eruption most commonly occurring in HIV-infected patients and presenting with recurrent crops of follicular papules and pustules predominantly involving the head, neck, and upper trunk (",
"      <a class=\"graphic graphic_picture graphicRef54404 graphicRef87125 \" href=\"UTD.htm?34/48/35591\">",
"       picture 6A-B",
"      </a>",
"      ). Peripheral eosinophilia is often present. Histology reveals infiltration of eosinophils into hair follicles and perifollicular areas (",
"      <a class=\"graphic graphic_picture graphicRef78005 graphicRef67192 \" href=\"UTD.htm?22/7/22649\">",
"       picture 7A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039192\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29755924\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the acneiform eruption should be individualized for each patient, based upon the type, severity, and location of the lesions, and the necessity of continuing treatment with EGFR inhibitors. Management in consultation with a dermatologist is suggested for most patients, and particularly if the skin reaction does not improve within two weeks of treatment, is severe (grade 3 to 4 (",
"    <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"     table 1",
"    </a>",
"    )), or has atypical appearance or distribution. (See",
"    <a class=\"local\" href=\"#H195039141\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Given the paucity of clinical trials, the treatment of EGFR inhibitor-induced acneiform eruption is largely based upon clinical experience, consensus statements, and local guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/64-67\">",
"     64-67",
"    </a>",
"    ]. Treatment options include topical and systemic corticosteroids, topical and systemic antibiotics, and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/45,68\">",
"     45,68",
"    </a>",
"    ]. The choice and progression of treatment is generally guided by the severity of the skin eruption and response to initial therapy. Grading the severity of rash is discussed above. (See",
"    <a class=\"local\" href=\"#H195039171\">",
"     'Grading of severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699849803\">",
"    <span class=\"h2\">",
"     Treatment of pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral H1 antihistamines, including sedating (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    ) or nonsedating agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    ), may be beneficial for patients with pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/48,64\">",
"     48,64",
"    </a>",
"    ]. In a clinical trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    (a neurokinin 1 receptor antagonist) was effective in reducing pruritus intensity by &gt;80 percent in 41 of 45 patients treated with EGFR and TK inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/69\">",
"     69",
"    </a>",
"    ]. Pruritus did not recur in 87 percent of patients during the 90-day study period. However, aprepitant should be used with caution in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , since aprepitant-induced inhibition of the liver cytochrome P450 3A4 may increase the trough levels of erlotinib [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GABA agonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    may be tried if oral antihistamines are ineffective. Evidence of benefit in patients with acneiform eruption secondary to EGFR inhibitors is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/71\">",
"     71",
"    </a>",
"    ], but they are used to treat other forms of chronic pruritus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link&amp;anchor=H8354445#H8354445\">",
"     \"Pruritus: Overview of management\", section on 'Anticonvulsants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29755685\">",
"    <span class=\"h2\">",
"     Patients with grade 1 rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with grade 1 rash (",
"    <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"     table 1",
"    </a>",
"    ), we usually suggest topical corticosteroids and topical antibiotics. We typically use low potency topical corticosteroids (group six (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 4",
"    </a>",
"    )) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    1% gel twice a day for four weeks.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    3% gel or cream or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    0.75% to 1%",
"    <span class=\"nowrap\">",
"     cream/gel",
"    </span>",
"    also may be used.",
"   </p>",
"   <p>",
"    We generally reassess patients after four weeks of treatment. If the acneiform eruption has not improved or has worsened, patients are treated in the same way as those with grade 2 rash.",
"   </p>",
"   <p>",
"    The use of topical corticosteroids and antibiotics for the treatment of the acneiform eruption has not been evaluated in randomized trials. Our suggestion for their use is based upon case series and case reports and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/64,68,72-76\">",
"     64,68,72-76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29755709\">",
"    <span class=\"h2\">",
"     Patients with grade 2 rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with grade 2 rash (",
"    <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"     table 1",
"    </a>",
"    ), we suggest topical corticosteroids and oral tetracyclines. We use low potency topical corticosteroids (group six (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 4",
"    </a>",
"    )) twice a day for at least four weeks and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    100 mg twice per day for four to six weeks.",
"   </p>",
"   <p>",
"    If a patient with grade 2 rash is already on an oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , an alternative antibiotic such as a first-generation oral cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    500 mg twice per day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"     cefadroxil",
"    </a>",
"    500 mg twice per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    160",
"    <span class=\"nowrap\">",
"     mg/sulfamethoxazole",
"    </span>",
"    800 mg twice per day) can be given for two weeks. If viral or bacterial superinfection is suspected, cultures of exudates should be obtained prior to the initiation of the antibiotic to determine appropriate antimicrobial therapy.",
"   </p>",
"   <p>",
"    We generally reassess patients after two weeks of treatment. If no improvement or worsening is noted after two weeks of treatment, patients are treated in the same way as those with grade &ge;3 rash. &nbsp;",
"   </p>",
"   <p>",
"    The use of topical corticosteroids and oral antibiotics for the treatment of the acneiform eruption has not been evaluated in randomized trials. Their use is based upon case series and case reports and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/64,68,72-76\">",
"     64,68,72-76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662500\">",
"    <span class=\"h2\">",
"     Patients with grade &ge;3 rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with grade &ge;3 (",
"    <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"     table 1",
"    </a>",
"    ), intolerable rash, or rash that interferes with self-care activities of daily living or impairs the quality of life, dose modification of EGFR inhibitors may be warranted. Modification of EGFR inhibitor therapy should occur according to the instructions provided in the prescribing information for the particular agent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/45,68\">",
"     45,68",
"    </a>",
"    ]. Dose modification is maintained until improvement to grade &le;2.",
"   </p>",
"   <p>",
"    In addition to dose modification of EGFR inhibitor therapy, we suggest treatment with oral antibiotics plus a short course of systemic corticosteroids. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    100 mg is given twice a day for at least four weeks. First-generation oral cephalosporins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    500 mg twice per day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"     cefadroxil",
"    </a>",
"    500 mg twice per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    160",
"    <span class=\"nowrap\">",
"     mg/sulfamethoxazole",
"    </span>",
"    800",
"    <span class=\"nowrap\">",
"     mg/twice",
"    </span>",
"    per day) given for four weeks can be used as alternatives when patients do not benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    antibiotics or have a culture-proven infection with organisms resistant to tetracycline antibiotics. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to a maximum of 40 mg per day is given for seven days.",
"   </p>",
"   <p>",
"    Improvement should be noted within two weeks. If a viral or bacterial superinfection is suspected, cultures of exudates should be obtained prior to the initiation of the antibiotic treatment to determine appropriate antimicrobial therapy.",
"   </p>",
"   <p>",
"    Oral corticosteroids for the treatment of severe acneiform eruption have not been evaluated in randomized trials and their use is based upon their antiinflammatory properties and clinical experience. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27163434\">",
"    <span class=\"h3\">",
"     Refractory grade &ge;3 rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with grade &ge;3 rash that does not improve with the regimen described above, low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (20 to 30 mg per day) may be tried [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/72\">",
"     72",
"    </a>",
"    ]. Oral tetracyclines are discontinued before initiating oral isotretinoin. Improvement is generally evident within four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/77\">",
"     77",
"    </a>",
"    ]; therapy is continued for at least two months after patients resume EGFR inhibitor at regular dose.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     Isotretinoin",
"    </a>",
"    may aggravate some EGFR inhibitor adverse effects such as skin dryness, cheilitis, or photosensitivity. Skin dryness and cheilitis can be alleviated by the application of alcohol-free emollients multiple times per day. Patients with increased photosensitivity should adopt sun protection measures, which include limiting the exposure to the sun, wearing protective clothing, and regular use of sunscreens with SPF &ge;30. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link&amp;anchor=H9#H9\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Mucocutaneous side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no improvement or worsening is noted despite dose modification, treatment with systemic antibiotics and systemic corticosteroids, or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , interruption or discontinuation of EGFR inhibitor treatment may be necessary. Decisions regarding interruption or discontinuation of EGFR inhibitor therapy must involve the patient, the patient&rsquo;s oncologist, and the patient&rsquo;s dermatologist; the potential risks and benefits and the patient&rsquo;s values and preferences must be considered.",
"   </p>",
"   <p>",
"    The evidence for efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    for severe acneiform eruption is limited to single case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. Indirect evidence of efficacy is derived from studies of treatment of acne vulgaris. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link&amp;anchor=H3169690#H3169690\">",
"     \"Treatment of acne vulgaris\", section on 'Oral isotretinoin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52639361\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52639369\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiating treatment with EGFR inhibitors, patients should be educated about adopting general skin care measures, which include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Regularly using a broad-spectrum",
"      <span class=\"nowrap\">",
"       (UVA/UVB)",
"      </span>",
"      sunscreen with SPF &ge;15 with inorganic ingredients (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      , titanium dioxide)",
"     </li>",
"     <li>",
"      Limiting excessive sun exposure",
"     </li>",
"     <li>",
"      Using thick, alcohol-free emollients twice daily",
"     </li>",
"     <li>",
"      Avoiding over the counter anti-acne medications and alcohol-based skin care products",
"     </li>",
"     <li>",
"      Reducing the frequency and duration of hot showers",
"     </li>",
"     <li>",
"      Using",
"      <span class=\"nowrap\">",
"       tepid/lukewarm",
"      </span>",
"      water for bathing",
"     </li>",
"     <li>",
"      Avoiding antibacterial or perfumed soaps and detergents",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52639376\">",
"    <span class=\"h2\">",
"     Preemptive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest prophylactic oral tetracyclines for patients initiating treatment with EGFR inhibitors. Treatment is started on the same day as EGFR inhibitor therapy. We typically use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg twice a day or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    100 mg daily for six to eight weeks.",
"   </p>",
"   <p>",
"    In a 2012 meta-analysis of four placebo-controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/80-83\">",
"     80-83",
"    </a>",
"    ] including 351 patients, patients who initiated prophylactic treatment with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    on the same day or the day before initiating EGFR inhibitor therapy had a decreased incidence of moderate to severe (grade &ge;2 (",
"    <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"     table 1",
"    </a>",
"    )) folliculitis (combined odds ratio 0.19, 95% CI 0.12-0.31) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/84\">",
"     84",
"    </a>",
"    ]. However, the benefit was lost after discontinuation of treatment. The incidence of mild (grade 1 (",
"    <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"     table 1",
"    </a>",
"    )) folliculitis was not changed by prophylactic tetracyclines. The data were insufficient to determine the optimal treatment regimen and duration.",
"   </p>",
"   <p>",
"    The efficacy of topical treatments alone or in conjunction with oral antibiotics for the prevention of acneiform eruption has not been adequately evaluated. In a randomized trial of patients initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    therapy with or without prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    0.05% cream applied to one side of the face was not effective in preventing the acneiform eruption when used as a single agent and provided little benefit beyond that seen with minocycline alone when used in combination with oral minocycline [",
"    <a class=\"abstract\" href=\"UTD.htm?9/6/9322/abstract/80\">",
"     80",
"    </a>",
"    ]. In addition, tazarotene was associated with significant skin irritation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195039241\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The acneiform (papulopustular) eruption is the prototypical cutaneous adverse reaction to treatment with EGFR inhibitors. It occurs in over 80 percent of patients and is more frequent in older patients and in patients with light skin phototypes (",
"      <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H195039099\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H195039106\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The eruption develops mainly in areas rich in sebaceous glands (eg, scalp, face, upper trunk) within the first two weeks of therapy (",
"      <a class=\"graphic graphic_picture graphicRef55753 \" href=\"UTD.htm?21/20/21827\">",
"       picture 1",
"      </a>",
"      ). Erythematous papules and pustules evolve to crusted lesions and eventually resolve leaving persistent erythema, telangiectasias, and skin dryness. Bacterial superinfection may occur. (See",
"      <a class=\"local\" href=\"#H195039141\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3611686\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acneiform eruption in patients receiving EGFR inhibitor therapy is usually straightforward, based upon the morphology and distribution of the skin lesions (eg, erythematous and follicular papules or pustules in areas rich in sebaceous glands with sparing of palmoplantar surfaces) (",
"      <a class=\"graphic graphic_picture graphicRef55753 \" href=\"UTD.htm?21/20/21827\">",
"       picture 1",
"      </a>",
"      ). The severity is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 (",
"      <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H195039162\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest prophylactic oral tetracyclines for patients initiating treatment with EGFR inhibitors (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Treatment is started on the same day as EGFR inhibitor therapy. We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg twice a day or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      100 mg daily for six to eight weeks. (See",
"      <a class=\"local\" href=\"#H52639376\">",
"       'Preemptive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with grade 1 rash (",
"      <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"       table 1",
"      </a>",
"      ), we suggest topical corticosteroids with or without topical antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use low potency topical corticosteroids (group six (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 4",
"      </a>",
"      )) twice a day for four weeks and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      1% gel twice a day for four weeks. (See",
"      <a class=\"local\" href=\"#H29755685\">",
"       'Patients with grade 1 rash'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with grade 2 rash (",
"      <a class=\"graphic graphic_table graphicRef86990 \" href=\"UTD.htm?10/33/10768\">",
"       table 1",
"      </a>",
"      ) who are not taking prophylactic tetracyclines, we suggest topical corticosteroids and oral tetracyclines (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use low potency topical corticosteroids (group six (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 4",
"      </a>",
"      )) twice a day for four weeks and either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      100 mg orally twice a day for four weeks. First-generation oral cephalosporins (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"       cefadroxil",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      can be used as alternative antibiotics for patients who are taking prophylactic tetracyclines or do not benefit from tetracyclines. (See",
"      <a class=\"local\" href=\"#H29755709\">",
"       'Patients with grade 2 rash'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with grade &ge;3 rash who are not taking prophylactic tetracyclines, we suggest treatment with oral tetracyclines plus a short course of systemic corticosteroids in addition to EGFR inhibitor dose modification (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      100 mg orally twice a day for at least four weeks and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally once per day for seven days. First-generation oral cephalosporins (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"       cefadroxil",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      can be used as alternative antibiotics for patients who are taking prophylactic tetracyclines or do not benefit from tetracyclines. (See",
"      <a class=\"local\" href=\"#H662500\">",
"       'Patients with grade &ge;3 rash'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/1\">",
"      Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/2\">",
"      Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/3\">",
"      Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006; 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/4\">",
"      Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/5\">",
"      Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008; 13:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/6\">",
"      Boone SL, Rademaker A, Liu D, et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007; 72:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/7\">",
"      P&eacute;rez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/8\">",
"      Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/9\">",
"      Jatoi A, Green EM, Rowland KM Jr, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009; 77:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/10\">",
"      Luu M, Boone SL, Patel J, et al. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clin Exp Dermatol 2011; 36:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/11\">",
"      Peus D, Vasa RA, Meves A, et al. UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival. Photochem Photobiol 2000; 72:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/12\">",
"      Jatoi A, Thrower A, Sloan JA, et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 2010; 15:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/13\">",
"      Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/14\">",
"      Hughes AN, O'Brien ME, Petty WJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/15\">",
"      Balagula Y, Wu S, Su X, Lacouture ME. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Ann Oncol 2011; 22:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/16\">",
"      Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/17\">",
"      Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/18\">",
"      Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8 Suppl 1:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/19\">",
"      Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13:3913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/20\">",
"      Per&eacute;z-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/21\">",
"      Fiala O, Pesek M, Finek J, et al. Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice. Neoplasma 2013; 60:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/22\">",
"      Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013; 132:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/23\">",
"      Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012; 78:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/24\">",
"      Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012; 30:2861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/25\">",
"      Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/26\">",
"      Nanney LB, Stoscheck CM, King LE Jr, et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/27\">",
"      Nanney LB, Magid M, Stoscheck CM, King LE Jr. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/28\">",
"      Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/29\">",
"      Han SS, Lee M, Park GH, et al. Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br J Dermatol 2010; 162:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/30\">",
"      Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/31\">",
"      Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/32\">",
"      Rodeck U, Jost M, Kari C, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 1997; 110 ( Pt 2):113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/33\">",
"      Lorch JH, Klessner J, Park JK, et al. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem 2004; 279:37191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/34\">",
"      Guttman-Yassky E, Mita A, De Jonge M, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010; 46:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/35\">",
"      Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/36\">",
"      Murillas R, Larcher F, Conti CJ, et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14:5216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/37\">",
"      Surguladze D, Deevi D, Claros N, et al. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res 2009; 69:5643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/38\">",
"      Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 2010; 15:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/39\">",
"      Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/40\">",
"      Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 2010; 16:4452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/41\">",
"      Ro&eacute; E, Garc&iacute;a Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006; 55:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/42\">",
"      Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010; 116:3916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/43\">",
"      Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/44\">",
"      de Noronha e Menezes NM, Lima R, Moreira A, et al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol 2009; 19:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/45\">",
"      Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/46\">",
"      Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/47\">",
"      Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/48\">",
"      Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/49\">",
"      Eilers RE Jr, Gandhi M, Patel JD, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010; 102:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/50\">",
"      Li J, Peccerillo J, Kaley K, Saif MW. Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP 2009; 10:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/51\">",
"      Grenader T, Gipps M, Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008; 9:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/52\">",
"      Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009; 7 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/53\">",
"      Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/54\">",
"      Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007; 21:34.",
"     </a>",
"    </li>",
"    <li>",
"     CTCAE v 4.0 www.evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on September 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/56\">",
"      Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012; 67:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/57\">",
"      Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007; 25:5121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/58\">",
"      Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011; 50:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/59\">",
"      Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol 2011; 165:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/60\">",
"      Mah&eacute; E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006; 55:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/61\">",
"      Campistol JM, de Fijter JW, Flechner SM, et al. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010; 24:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/62\">",
"      Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/63\">",
"      Balagula Y, Barth Huston K, Busam KJ, et al. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011; 29:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/64\">",
"      Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/65\">",
"      Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005; 3:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/66\">",
"      Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs 2008; 12:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/67\">",
"      Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/68\">",
"      Melosky B, Burkes R, Rayson D, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/69\">",
"      Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012; 13:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/70\">",
"      Mir O, Coriat R. Aprepitant for pruritus: drug-drug interactions matter. Lancet Oncol 2012; 13:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/71\">",
"      Porzio G, Aielli F, Verna L, et al. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage 2006; 32:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/72\">",
"      Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/73\">",
"      Thatcher N, Nicolson M, Groves RW, et al. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. Oncologist 2009; 14:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/74\">",
"      Gutzmer R, Becker JC, Enk A, et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges 2011; 9:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/75\">",
"      Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011; 16:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/76\">",
"      Gerber PA, Meller S, Eames T, et al. Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. Eur J Med Res 2012; 17:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/77\">",
"      Requena C, Llombart B, Sanmart&iacute;n O. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin. Cutis 2012; 90:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/78\">",
"      DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007; 56:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/79\">",
"      Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005; 153:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/80\">",
"      Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25:5390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/81\">",
"      Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/82\">",
"      Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/83\">",
"      Deplanque G, Chavaillon J, Vergnenegre A. CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 2010; 28:640s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/6/9322/abstract/84\">",
"      Bachet JB, Peuvrel L, Bachmeyer C, et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012; 17:555.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15764 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9322=[""].join("\n");
var outline_f9_6_9322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H195039241\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195039099\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195039106\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3612236\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31702946\">",
"      Relationship between rash and survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195039113\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H195039120\">",
"      Direct receptor inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H195039127\">",
"      Inflammatory response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H195039134\">",
"      Role of microorganisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3612515\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195039141\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3611686\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H699849676\">",
"      COMPLICATIONS AND SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H699849684\">",
"      Secondary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H699849441\">",
"      Cutaneous sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H699849637\">",
"      Impact on patients&rsquo; quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195039162\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3612688\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H195039171\">",
"      Grading of severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195039178\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195039192\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29755924\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H699849803\">",
"      Treatment of pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29755685\">",
"      Patients with grade 1 rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29755709\">",
"      Patients with grade 2 rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662500\">",
"      Patients with grade &ge;3 rash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27163434\">",
"      - Refractory grade &ge;3 rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52639361\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52639369\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52639376\">",
"      Preemptive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195039241\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15764\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15764|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/20/21827\" title=\"picture 1\">",
"      EGFR inhbtr acneiform erupt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/18/39204\" title=\"picture 2A\">",
"      Steroid acne 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/16/4359\" title=\"picture 2B\">",
"      Steroid acne 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/11/5303\" title=\"picture 3A\">",
"      Pityrosporum folliculitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/56/8069\" title=\"picture 3B\">",
"      Pityrosporum folliculitis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/62/23526\" title=\"picture 4A\">",
"      Tinea barbae 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/16/3333\" title=\"picture 4B\">",
"      Tinea barbae 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/2/4132\" title=\"picture 5\">",
"      Dermatophyte KOH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/2/33839\" title=\"picture 6A\">",
"      Eosinophilic folliculitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/37/20053\" title=\"picture 6B\">",
"      HIV-associated eosinophilic folliculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/19/33075\" title=\"picture 7A\">",
"      Eosinophilic folliculitis histology low power view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/35/1590\" title=\"picture 7B\">",
"      Eosinophilic folliculitis histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15764|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/33/10768\" title=\"table 1\">",
"      CTCAE grading scale for skin and subcutaneous disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 2\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/32/11787\" title=\"table 3\">",
"      Causes drug induced acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 4\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=related_link\">",
"      Laser and light therapy for cutaneous vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6021?source=related_link\">",
"      Malassezia infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=related_link\">",
"      Treatment of acne vulgaris",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_6_9323="Post-coital prophylaxis UTI";
var content_f9_6_9323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Post-coital antimicrobial prophylaxis regimens for women with recurrent urinary tract infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Regimens",
"      </td>",
"      <td class=\"subtitle1\">",
"       Expected UTIs per year",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trimethoprim-sulfamethoxazole 40 mg/200 mg",
"      </td>",
"      <td>",
"       0.30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trimethoprim-sulfamethoxazole 80 mg/400 mg",
"      </td>",
"      <td>",
"       0.00",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nitrofurantoin 50 mg or 100 mg",
"      </td>",
"      <td>",
"       0.10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cephalexin 250 mg",
"      </td>",
"      <td>",
"       0.03",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ciprofloxacin 125 mg",
"      </td>",
"      <td>",
"       0.00",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Norfloxacin 200 mg",
"      </td>",
"      <td>",
"       0.00",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ofloxacin 100 mg",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9323=[""].join("\n");
var outline_f9_6_9323=null;
var title_f9_6_9324="Vascular disease in Behcets";
var content_f9_6_9324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vascular disease in 728 patients with Behcet's disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Venous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deep venous thrombosis",
"       </td>",
"       <td>",
"        221",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subcutaneous thrombophlebitis",
"       </td>",
"       <td>",
"        205",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SVC occlusion",
"       </td>",
"       <td>",
"        122",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IVC occlusion",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebral sinus thrombosis",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Budd-Chiari syndrome",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other venous occlusion*",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Arterial disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary artery occlusion or aneurysm",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aortic aneurysm",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extremity arterial occlusion or aneurysm",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other arterial occlusion or aneurysm&bull;",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Right ventricular thrombus",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Other veins included subclavian, iliac, portal, renal, innominate, brachiocephalic.",
"     <br>",
"      &bull; Other arteries included iliac, subclavian, renal, carotid, cerebral, coronary, innominate, mesenteric, aorta, basilar, splenic.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Review of 728 cases from Koc, Y, Gullu, I, Akpek, G, et al. J Rheumatol 1992; 19:402.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9324=[""].join("\n");
var outline_f9_6_9324=null;
var title_f9_6_9325="FUdR dose modifications";
var content_f9_6_9325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    MSKCC guidelines for FUDR dose modification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        FUDR dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        AST",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reference value (ref)*",
"       </td>",
"       <td>",
"        &le;50 U/L",
"       </td>",
"       <td>",
"        &gt;50 U/L",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"4\">",
"        Current value&bull;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        0 to &lt;3 x ref",
"       </td>",
"       <td>",
"        0 to &lt;2 x ref",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to &lt;4 x ref",
"       </td>",
"       <td>",
"        2 to &lt;3 x ref",
"       </td>",
"       <td>",
"        80 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to &lt;5 x ref",
"       </td>",
"       <td>",
"        3 to &lt;4 x ref",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;5 x ref",
"       </td>",
"       <td>",
"        &ge;4 x ref",
"       </td>",
"       <td>",
"        HOLD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        If held, restart when:",
"       </td>",
"       <td>",
"        &lt;4 x ref",
"       </td>",
"       <td>",
"        &lt;3 x ref",
"       </td>",
"       <td>",
"        50 percent of last dose given",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Alkaline phosphatase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reference value (ref)",
"       </td>",
"       <td>",
"        &le;90 U/L",
"       </td>",
"       <td>",
"        &gt;90 U/L",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Current value",
"       </td>",
"       <td>",
"        0 to &lt;1.5 x ref",
"       </td>",
"       <td>",
"        0 to &lt;1.2 x ref",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.5 to &gt;2 x ref",
"       </td>",
"       <td>",
"        1.2 to 1.5 x ref",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;2 x ref",
"       </td>",
"       <td>",
"        &ge;1.5 x ref",
"       </td>",
"       <td>",
"        HOLD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        If held, restart when:",
"       </td>",
"       <td>",
"        &lt;1.5 x ref",
"       </td>",
"       <td>",
"        &lt;1.2 x ref",
"       </td>",
"       <td>",
"        25 percent of last dose given",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Total bilirubin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reference value (ref)",
"       </td>",
"       <td>",
"        &le;1.2 mg/dL",
"       </td>",
"       <td>",
"        &gt;1.2 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Current value",
"       </td>",
"       <td>",
"        0 to &lt;1.5 x ref",
"       </td>",
"       <td>",
"        0 to &lt;1.2 x ref",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.5 to &lt;2 x ref",
"       </td>",
"       <td>",
"        1.2 to &lt;1.5 x ref",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;2 x ref",
"       </td>",
"       <td>",
"        &ge;1.5 x ref",
"       </td>",
"       <td>",
"        HOLD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If held, restart when:",
"       </td>",
"       <td>",
"        &lt;1.5 x ref",
"       </td>",
"       <td>",
"        &lt;1.2 x ref",
"       </td>",
"       <td>",
"        25 percent of last dose given",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MSKCC: Memorial Sloan Kettering Cancer Center; FUDR: fluorodeoxyuridine; AST: aspartate aminotransaminase.",
"     <br>",
"      *&nbsp;Reference value is the value obtained on the day patient received last FUDR dose.",
"      <br>",
"       &bull; Current value is the value obtained at pump emptying or on the day of planned treatment (whichever is higher).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zalcberg JR, Kemeny NE. Systemic or regional chemotherapy for liver metastases from colorectal cancer: Has the wheel stopped spinning? Cancer J 2004; 10:271. Copyright &copy;2004 MediMedia.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9325=[""].join("\n");
var outline_f9_6_9325=null;
var title_f9_6_9326="Studies of systemic therapy for brain metastases breast cancer";
var content_f9_6_9326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected studies of systemic therapy for brain metastases from breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patient population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total number of&nbsp;patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number&nbsp;of&nbsp;patients with breast cancer and brain metastases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Objective response rate (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        TTP/PFS",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rosner et al",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        Various (CFP, CFPMV, MVP, CA)",
"       </td>",
"       <td>",
"        Breast cancer",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Case series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boogerd et al",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        Oral CMF (n=20), or CAF (n=2)",
"       </td>",
"       <td>",
"        Breast cancer",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Case series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Friedman et al",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        Temozolomide 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        days 1-7, 15-21, every 28 days",
"       </td>",
"       <td>",
"        Solid tumors",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        No responses seen in breast cancer patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Siena et al",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        Temozolomide 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        days 1-7, 15-21, every 28 days",
"       </td>",
"       <td>",
"        Solid tumors",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        19 (in subset of patients with breast cancer)",
"       </td>",
"       <td>",
"        1.9 months",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trudeau et al",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        Temozolomide 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        days 1-7, 15-21, every 28 days",
"       </td>",
"       <td>",
"        Breast cancer",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rivera et al",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        Escalating doses of capecitabine and temozolomide",
"       </td>",
"       <td>",
"        Breast cancer",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        3 months",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Franciosi et al",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Cisplatin 100 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         day 1",
"        </p>",
"        <p>",
"         Etoposide 100 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         days 1, 3, and 5, every 21 days",
"        </p>",
"       </td>",
"       <td>",
"        Solid tumors",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        38 (in subset of patients with breast cancer)",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"       <td>",
"        No prior radiation therapy allowed; 36 percent of&nbsp;patients had not had prior systemic treatment for breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Christodoulou et al",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Temozolomide 150 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         days 1-5",
"        </p>",
"        <p>",
"         Cisplatin 75 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         day 1, every 21 days",
"        </p>",
"       </td>",
"       <td>",
"        Solid tumors",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        40 (in subset of patients with breast cancer)",
"       </td>",
"       <td>",
"        2.9 months",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lin et al",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        Lapatinib",
"       </td>",
"       <td>",
"        HER2+ breast cancer",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        3 months",
"       </td>",
"       <td>",
"        64 percent had two or more prior lines of systemic treatment (trastuzumab plus chemotherapy)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lin et al",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        Lapatinib",
"       </td>",
"       <td>",
"        HER2+ breast cancer",
"       </td>",
"       <td>",
"        237",
"       </td>",
"       <td>",
"        237",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2.4 months",
"       </td>",
"       <td>",
"        All patiens previously treated with radiation therapy; overall survival was 6 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TTP: time to tumor progression; PFS: progress-free survival; NR: not reported; CFP: cyclophosphamide, fluorouracil, and prednisone; CFPMV: cyclophosphamide, fluorouracil, and prednisone plus methotrexate and vincristine; MVP: methotrexate, vincristine, and prednisone; CA: cyclophosphamide and adriamycin; CMF: cyclophosphamide, methotrexate, and fluorouracil; CAF: cyclophosphamide, doxorubicin, and fluorouracil; HER2+: human epidermal growth factor receptor 2.",
"    </div>",
"    <div class=\"reference\">",
"     1. Rosner D, Nemoto T,&nbsp;Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58:832.",
"     <br>",
"      2. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992; 69:972.",
"      <br>",
"       3. Friedman HS, Evans, B and Reardon, DA. Phase II trial of temozolomide for patients with progressive brain metastases (abstract #408). Proc Am Soc Clin Oncol 2003; 22:102.",
"       <br>",
"        4. Siena S, Landonio G, Beaietta E. Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer (abstract #407). Proc Am Soc Clin Oncol 2003; 22:407.",
"        <br>",
"         5. Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006; 17:952.",
"         <br>",
"          6. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107:1348.",
"          <br>",
"           7. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85:1599.",
"           <br>",
"            8. Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005; 71:61.",
"            <br>",
"             9. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26:1993.",
"             <br>",
"              10. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15:1452.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9326=[""].join("\n");
var outline_f9_6_9326=null;
var title_f9_6_9327="TEE right left atria";
var content_f9_6_9327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Left and right atria on transesophageal echocardiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 203px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recorded in the horizontal (0&ordm;) plane, panel A shows the left atrium (LA), right atrium (RA), interatrial septum, tricuspid valve (TV) leaflets, and right upper pulmonary vein (RUPV). Panel B shows normal color Doppler flow (red/orange) of blood entering the LA from the RUPV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_6_9327=[""].join("\n");
var outline_f9_6_9327=null;
